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Abstract
A new class of severe but treatable autoimmune encephalitides is associated with serum and CSF
autoantibodies to cell surface receptors that are thought to cause disease by disrupting the normal
function of their target protein. Consistent with disruption of the major neurotransmission pathways and
thus circuit malfunction in the central nervous system, symptoms of these newly characterized diseases
are severe and include psychosis, memory loss, confusion, seizures, and autonomic instability normal
function. The majority of symptoms resolve with aggressive immunosuppresive therapy.
The best characterized of these encephalitides is associated with antibodies to ionotropic glutamate
receptors, N-methyl-D-aspartate receptor (NMDAR) or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPAR). NMDAR and AMPAR autoantibodies cross-link the cognate synaptic receptors on
the surface of cultured neurons and result in a selective internalization of the target without disruption of
any other synaptic component or injury to neurons. In a passive transfer animal model, chronic perfusion
of NMDAR antibodies into the cerebrospinal fluid (CSF) of mice also decreases NMDA receptors after 14
days, which results in anhedonia and diminished spatial memory. Consistent with the reversible course of
disease, the effects of NMDAR and AMPAR autoantibodies can be reversed in both in vivo and in vitro
model systems. These mechanisms may underlie the neurological and psychiatric manifestations of
these forms of autoimmune encephalitis, and account for recovery of many patients with immune therapy
aimed at lowering antibody titer.
Patients with antibodies to the metabotropic gamma-aminobutyric acid receptor type B (GABAB receptor)
develop severe intractable seizures, but little is known about the underlying pathophysiological
mechanisms. Deletion mapping and expression in heterologous cells showed that patient anti-GABAB
antibodies bind to alternatively spliced Sushi domains present in the presynaptically localized GABAB1a
isoform. In contrast to patient anti-NMDAR antibodies, GABAB autoantibodies did not result in a decrease
in surface GABAB receptors or their internalization. Treating neurons with GABABR autoantibodies for two
hours blocked the activation of GABAB receptors by baclofen in a titer-dependent manner. Autoantibodybound GABABRs are still signaling competent, because baclofen block was circumvented by directly
activating GABAB2 with a selective agonist, CGP7930.
Patient GABAB receptor autoantibodies are selective GABAB1 antagonists that may contribute to seizures
by interfering with GABA-mediated inhibition. Brain penetrant GABAB2 agonists may be useful to treat
intractable seizures in anti-GABAB receptor encephalitis patients.
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ABSTRACT
SYNAPTIC, CELLULAR AND BEHAVIORAL PATHOPHYSIOLOGY IN ANTI-GABAB
RECEPTOR AND ANTI-NMDA RECEPTOR ENCEPHALITIDES

Ankit Jain
Rita J. Balice-Gordon

A new class of severe but treatable autoimmune encephalitides is associated with
serum and CSF autoantibodies to cell surface receptors that are thought to cause
disease by disrupting the normal function of their target protein. Consistent with
disruption of the major neurotransmission pathways and thus circuit malfunction in the
central nervous system, symptoms of these newly characterized diseases are severe
and include psychosis, memory loss, confusion, seizures, and autonomic instability
normal function. The majority of symptoms resolve with aggressive immunosuppresive
therapy.
The best characterized of these encephalitides is associated with antibodies to
ionotropic glutamate receptors, N-methyl-D-aspartate receptor (NMDAR) or α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR). NMDAR and AMPAR
autoantibodies cross-link the cognate synaptic receptors on the surface of cultured
neurons and result in a selective internalization of the target without disruption of any
other synaptic component or injury to neurons. In a passive transfer animal model,
chronic perfusion of NMDAR antibodies into the cerebrospinal fluid (CSF) of mice also
decreases NMDA receptors after 14 days, which results in anhedonia and diminished
v

spatial memory. Consistent with the reversible course of disease, the effects of NMDAR
and AMPAR autoantibodies can be reversed in both in vivo and in vitro model systems.
These mechanisms may underlie the neurological and psychiatric manifestations of
these forms of autoimmune encephalitis, and account for recovery of many patients with
immune therapy aimed at lowering antibody titer.
Patients with antibodies to the metabotropic gamma-aminobutyric acid receptor
type B (GABAB receptor) develop severe intractable seizures, but little is known about
the underlying pathophysiological mechanisms. Deletion mapping and expression in
heterologous cells showed that patient anti-GABAB antibodies bind to alternatively
spliced Sushi domains present in the presynaptically localized GABAB1a isoform. In
contrast to patient anti-NMDAR antibodies, GABAB autoantibodies did not result in a
decrease in surface GABAB receptors or their internalization. Treating neurons with
GABABR autoantibodies for two hours blocked the activation of GABAB receptors by
baclofen in a titer-dependent manner. Autoantibody-bound GABABRs are still signaling
competent, because baclofen block was circumvented by directly activating GABAB2 with
a selective agonist, CGP7930.
Patient GABAB receptor autoantibodies are selective GABAB1 antagonists that may
contribute to seizures by interfering with GABA-mediated inhibition. Brain penetrant
GABAB2 agonists may be useful to treat intractable seizures in anti-GABAB receptor
encephalitis patients.
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PREFACE
Recently, several novel, potentially lethal and treatment-responsive syndromes that
affect hippocampal and cortical function have been shown to be associated with autoantibodies against synaptic antigens, notably glutamate or GABAB receptors. Patients
with these autoantibodies (sometimes associated with teratomas and other neoplasms)
present with psychiatric symptoms, seizures, memory deficits and decreased levels of
consciousness. These symptoms often improve dramatically after immunotherapy or
tumor resection. In this work I review and extend several studies of the cellular and
synaptic effects of these antibodies in hippocampal neurons in vitro and preliminary work
in rodent models. Our work suggests that patient antibodies lead to rapid and reversible
removal of neurotransmitter receptors from synapses, leading to changes in synaptic
and circuit function that, in turn, are likely to lead to behavioral deficits. I also discuss
several of the many questions raised by these and related disorders. Determining the
mechanisms underlying these novel anti-neurotransmitter receptor encephalitides will
provide insights into the cellular and synaptic bases of the memory and cognitive deficits
that are hallmarks of these disorders, and potentially suggest avenues for therapeutic
intervention.
In my thesis, I have focused on the pathophysiological mechanisms of two
autoimmune encephalitides, one associated with anti-NMDA receptor antibodies, and
the other associated with anti-GABAB receptor antibodies. The investigation of these
diseases ranges from patient-oriented research to mechanistic experiments in cell
culture and in animal models. The rich tapestry of clinical and mechanistic insights into
this new class of diseases caused by

neuronal cell surface autoantibodies is
ix

introduced in Chapter 1. Rapid progress has been made in our understanding of these
diseases since the discovery of anti-NMDA receptor encephalitis as the founding
member of this class of autoimmune disease in 2003. Since then, many previously
known as well as newly identified syndromes have been found to be caused by
autoantibodies to a diverse group of surface proteins such as neurotransmitter
receptors, synaptic scaffolding proteins, and also proteins whose function has not yet
been discovered.
In Chapter 2, I explore the mechanistic underpinnings of pathogenesis by GABAB
autoantibodies in a neuronal cell culture model. The autoantibodies in anti-GABAB
receptor encephalitis affect GABAB receptor function by a mechanism distinct from what
has been described thus far for anti-NMDA receptor, anti-AMPA receptor and antiGABAA receptor encephalitis. Rather than decreasing the level of GABAB receptors at
the surface of neurons, GABAB autoantibodies directly antagonize the activation of
GABAB receptors.
In Chapter 3, I present a multi-center collaborative effort to generate and describe a
passive immunization model of anti-NMDA receptor encephalitis. My role in this work
was to generate the animal model, and discover the conditions and tools that resulted in
a successful infusion of anti-NMDA receptor encephalitis patient CSF into mouse
cerebral ventricles. Like in vitro, exposure of mouse brains to patient CSF reduces
NMDA receptor levels and results in defects in spatial and object memory. Remarkably,
both the reduction in NMDA receptor levels and the cognitive decline recovers after the
cessation of patient CSF infusion. This animal model will be vital to test potential
therapeutic interventions that may reduce receptor loss and cognitive decline or hasten
recovery.
In Chapter 4, I describe a small

case series of the first known pregnant
x

women with anti-NMDA receptor encephalitis. The two term infants potentially exposed
to anti-NMDA receptor antibodies in utero did not have any signs of encephalitis.
The importance of these disorders is that they offer human models of brain–
immune interactions in which the target antigens have critical roles in neuronal synaptic
transmission and plasticity. Therefore, their study will improve our understanding of the
effects of the antibodies at the cellular, synaptic and circuit levels, eventually impacting
the clinical management of the patients.
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CHAPTER 1. Introduction
Cellular, synaptic and circuit effects of antibodies in synaptic
autoimmune encephalitides

Ankit Jain1 and Rita Balice-Gordon1,2

1

Department of Neuroscience, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA 19104
2

Neuroscience Research Unit, Pfizer, Inc., Cambridge, MA 02139
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Establishing a pathogenic role for anti-synaptic antibodies
Multiple lines of evidence strongly suggest that anti-synaptic antibodies are not
simply markers of disease but rather are directly pathogenic. When live,
unpermeabilized dissociated rodent brain cells are treated with patient CSF,
immunoglobulins (IgG) isolated from patient CSF or serum, unique patterns of punctate
surface staining are observed (Fig. 2A; Ances et al., 2005). This shows that patient
derived antibodies bind distinct neuronal cell surface proteins. This is in contrast to
classically described paraneoplastic autoimmune encephalitides, in which the isolated
antibodies target intracellular antigens, resulting in a cytotoxic T cell response, neuronal
cell death and a result, poor prognosis (Dalmau and Rosenfeld, 2008). In the case of
synaptic autoimmune encephalitides rodent brain sections immunostained with patient
CSF also show distinct patterns of immunoreactivity in the neuropil of hippocampus,
cortex and other brain regions, while there is no immunoreactivity to neuronal cell bodies
(Vitaliani et al., 2005). Brain biopsies from a small number of patients demonstrate
minimal pathologic changes or cell loss but demonstrate rare T cell and B cell infiltrates,
microgliosis and astrocytosis (Fig. 4; Martinez-Hernandez et al., 2011). These results
are consistent with a direct pathogenic role for patient antibodies in synaptic
autoimmunities rather than a cell mediated immune response as seen in paraneoplastic
encephalitides associated with intracellular antigens.
Mass spectrometry has been particularly useful for identifying specific binding
targets of anti-synaptic antibodies from immunoprecipitates of rat brain lysates with
patient antibdodies (Fig. 2C; Lai et al., 2009; Lancaster et al., 2011). Immunostaining of
heterologous cells that overexpress an antigenic candidate protein identified by mass
spectrometry with patient CSF has been used to confirm binding of patient antibodies to
a particular antigenic protein (Fig.

2D-F). These in vitro approaches,
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together with other analyses, have been used to establish that each distinct syndrome
corresponds to a distinct cell surface antigen targeted by patient CSF antibodies (Fig. 1).
The function of a surface protein antigen and the particular neuropsychiatric
encephalitis syndrome associated with that antigen are, not surprisingly, strongly
correlated. Moreover, the titer of a specific antibody is correlated to disease severity.
Upon aggressive immunomodulation therapy, these patient often improve in concert with
a decrease in antibody titer of the CSF (Dalmau et al., 2008; Florance et al., 2009),
although many patients can have positive antibody titers several years after their
recovery. Work from several labs has shown that associated antibodies likely cause the
neuronal and circuit abnormalities that manifest as neuropsychiatric symptoms, using
several complementary approaches.
In assays of antibody-antigen binding that rely on immunoprecipitation or
radioligands, it is not possible to distinguish between binding of antibody directly to the
protein of interest or to a non-antigenic protein that is bound to the antigenic protein in a
multiunit complex. To show that the putative target antigen is indeed sufficient to bind
patient antibodies, it is important to demonstrate that patient antibodies can immunostain
heterologous cells exogenously expressing the putative target antigen, and do not bind
to heterologous cells not expressing the exogenous protein. The CSF of autoimmune
encephalitis patients may contain antibodies against several distinct antigens, and the
results from immunoprecipitation, neuronal staining and heterologous cell staining would
be consistent with the possibility of antibodies to multiple antigens. To show that the
putative target antigen is specific and necessary to bind to immunoglobulins in a
patient’s CSF, a demonstration that patient antibodies do not bind to neuronal tissue
from rodents that lack the target antigen is required (Fig. 1).
3

Another confounding factor is that any effect of CSF on neurons in vitro or in vivo
may be the result of some factor(s) other than self-reactive immunoglobulins that does
not specifically bind to the putative target, for example elevated cytokines and other
sequelae of inflammation. To show that the immunoglobulin fraction of the CSF is
necessary and sufficient to disrupt normal functioning of the target antigen, one needs to
demonstrate that the effect of CSF is reproduced by IgG purified from CSF, but not by
the CSF fraction depleted of IgG. To confirm that antibodies cause neuronal dysfunction
and hence are the most likely candidate CSF factor to cause disease, the specific
antibodies are purified from CSF by incubation with immobilized antigen. Treatment with
this immunodepleted CSF results in no adverse effects on neurons, while the specific
antibodies purified from patient CSF recapitulate the effect of whole patient CSF. The
specific binding of antibodies along with an isolated change in the properties of the
cognate antigen provides a plausible biological mechanism for the causal link between
patient antibodies and the neuropsychiatric manifestation of the associated disease.

Cellular and synaptic mechanisms mediated by antibodies
Antibodies against ionotropic glutamate receptors
The best characterized autoimmune encephalitides in patients as well as in the
laboratory are ones associated with antibodies to ionotropic glutamate receptors: NMDA
receptors (NMDAR) and AMPA receptors (AMPAR). Anti-NMDAR encephalitis patients
classically present with severe aggression, paranoia, hallucinations and delusions
characteristic of acute psychosis along with personality changes and memory loss
(Dalmau et al., 2007; Sansing et al., 2007). Within days or weeks of the appearance of
psychiatric symptoms, patients begin to deteriorate neurologically; they have debilitating
seizures, decreased level of consciousness, abnormal movements, autonomic instability,
4

and hypoventilation. In contrast to the varied symptoms in anti-NMDAR encephalitis,
anti-AMPAR encephalitis most often presents with isolated memory loss and seizures
(Lai et al., 2009).
Both NMDARs and AMPARs transmit glutamatergic excitation, but serve distinct
functions at the cellular and circuit level. AMPA receptors mediate most of the fast
excitatory synaptic transmission in the brain (Shepherd and Huganir, 2007), while
NMDARs act as molecular coincidence directors. Open NMDARs allow calcium to enter
the postsynaptic cell where the high local concentration of calcium acts as a second
messenger. Together, they are essential for synaptic plasticity and memory.
NMDA receptors are usually formed from heteromers of two NR1 and two NR2
subunits (Kendrick et al., 1996; Laube and Kiderlen, 1997). There are four NR2 subunits
(NR2A-D), which have 50-70% sequence identity in the extracellular domain; NR1 is
ubiquitously distributed in the brain (Monyer et al., 1994; Standaert et al., 1994; Waxman
and Lynch, 2005). AMPA receptors are predominantly heterotetramers composed of
GluR1, 2, 3 or 4 subunits, and distinct combinations of subunits are expressed in a
region-specific manner (Palmer et al., 2005). GluR1/2 and GluR2/3 levels are high in
hippocampus and other limbic regions (Sprengel, 2006), similar to the distribution of
immunostaining with patients' antibodies.
There are several possible molecular mechanisms by which antibody binding to
synaptic proteins may result in a disruption in synaptic transmission that in turn alters
circuit properties pathologically. Antibody binding may block the agonist binding site or
inhibit conformational changes that promote the activation of receptors. In a classically
known autoimmune disease of the neuromuscular synapse, myasthenia gravis,
application of the pathogenic antibodies against nicotinic acetylcholine receptor
5

(nAChRs) from patients to outside-out patches of mouse myotubes irreversibly blocks
AChR currents (Jahn et al., 2000). In addition to agonist binding sites, both AMPAR and
NMDAR have additional N-terminal binding sites for channel modulators such as zinc
and polyamines that may be obscured by patients' antibodies (Rassendren et al., 1990;
Herin and Aizenman, 2004; Paoletti and Neyton, 2007).
On the opposite end of the spectrum, the antibodies may promote the active
conformation of the antigenic receptor and thus result in a constitutive or increased
activity of the receptor. NMDA receptor NR2 subunit specific antibodies from patients
with systemic lupus erythematosus (SLE) cause neuronal death when injected into
mouse brain (DeGiorgio et al., 2001). This effect is attenuated by treatment with the
NMDAR blocker, MK-801, suggesting the antibodies mediate cell death by enhancing
channel activation (DeGiorgio et al., 2001). Synaptic transmission is finely tuned over
many episodes of concurring electrical and biochemical activity in the cell. A change in
the gain of synaptic transmission by an exogenous agent can result in the loss of
information encoded by the synapse or even result in cellular injury from excitotoxicity or
increased intracellular calcium levels. Thus, either activation or inhibition of the cognate
receptor by antibodies may disrupt circuit dynamics by changing the finely tuned
synaptic gain or by causing cellular injury.
If antibody binding does not change the properties of the cognate antigen at the
molecular level, it can result in clustering of target receptors and their consequent
displacement from their multiprotein complexes at the synapse. This can change target
antigen localization in synaptic domains, deplete the target antigen by antibody mediated
capping and internalization, or even alter the turnover or intracellular trafficking of the
target antigen (Fig. 3A-C). Any of these possibilities would result in a loss of the role of
the target receptor at synapses and

hence adversely affect synaptic
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transmission. In addition to an acute blockade of nAChR by pathogenic antibodies,
nAChR antibodies from patients with myasthenia gravis have also been observed to
cause a loss of surface nAChRs by cross-linking and internalization (Drachman et al.,
1978). Similarly, cross-linking and internalization of voltage gated calcium channels by
autoantibodies has also been shown to occur in patients with Lambert-Eaton syndrome
(Nagel et al., 1988; Peers et al., 1993).
In the anti-glutamate receptor encephalitides, incubation of cultured neurons with
patient CSF for 15-30 minutes does not change synaptic transmission mediated by
NMDARs or AMPARs (Moscato et al., 2014, Peng et al., 2014). However, both antiNMDAR1 and anti-AMPAR antibodies decrease the frequency and amplitude of mini
EPSCs (Hughes et al., 2010; Moscato et al., 2014; Peng et al., 2014) within 12 hours of
CSF treatment. This loss of glutamatergic signaling at the synapse after several hours of
exposure of neurons to patient CSF is due to a reversible loss of receptors from
synapses. For both diseases, incubation of neurons grown 14 to 21 days in vitro and
treated with patient CSF for as little as 12 hours results in a titer-dependent decrease in
density of synaptic receptors monitored by immunostaining (Fig 3D-E). There is also a
decrease in the amount of surface receptors as seen by surface biotinylation followed by
western blotting, and a consistent decrease in receptor clusters that colocalize with other
synaptic proteins as assayed by immunostaining (Hughes et al., 2010; Moscato et al.,
2014). The receptors lost from the surface are internalized because a pool of antibody
bound receptors can be stained only upon permeabalization of the cell (Fig. 3B-C;
Moscato et al., 2014).
The molecular and subcellular effects of patient CSF on NMDA and AMPARs are
specific to the antigenic target of autoantibodies. The receptors are lost from the
synapse without affecting neuron

morphology, synapse density or the
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surface localization or amount of other synaptic proteins. In anti-NMDAR encephalitis,
despite a loss of NMDARs from synapses, there is no evidence for neuronal death,
synaptic pruning, or a loss of AMPARs or GABARs at either glutamatergic or gabaergic
synapses (Hughes et al., 2010). Similarly, anti-AMPAR antibodies exclusively affect
synaptic AMPARs, without a decrease in PSD-95, vesicular glutamate transporter,
NMDARs, or the AMPAR scaffolding protein, stargazin (Peng et al., 2014). This precise
molecular excision of the target antigen from synapses reflects the specificity of antitarget antibodies.
Remarkably, the synaptic loss of NMDARs or AMPARs is reversible. After
incubation for 24 hours, CSF can be washed out and replaced with culture medium. In
both cases, the cluster density of NMDARs or AMPARs returned to baseline within
several days. This reversibility of loss of synaptic glutamate receptors, together with the
fact that there is little or no neuron death after treatment with patient antibodies, may
explain the remarkable recovery of patients after CSF antibody titers are lowered by
immunotherapy. It is unclear, however, whether the prolonged time of recovery (usually
several months) represents persistence of the immune response in the brain or slow
recovery of circuit dysfunction caused by the decrease of synaptic proteins like NMDARs
and AMPARs that are critical for synaptic function and plasticity.
More is known about the mechanism of synaptic loss of NMDARs and AMPARs
than other antigens. NMDARs that are lost from the surface are internalized into
recycling endosomes and to some degree in degradation lysosomes (Moscato et al.,
2014). This internalization effect of patient antibodies can be lost if the antibodies are
converted into Fab fragments and lose their divalency (Fig. 2H). The divalency seems to
be more important than the presence of the Fc domain as clustering the NMDAR bound
Fab fragment with a second divalent

anti-Fab antibody restores the ability of
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the pathogenic antibodies to internalize NMDAR (Hughes et al., 2010). This requirement
for divalency of the antibody-antigen complex results in the sequestering of receptors in
clusters and this signals internalization of the receptor clusters. In vitro immunostaining
of neurons shows that treatment with patient CSF not only reduces the density of
receptor clusters, but the remaining clusters are much larger than in control treated
cultures. So, patient antibodies in anti-NMDAR encephalitis disrupt NMDAR contribution
to glutamatergic synapses by their clustering effect, and may not need to agonize or
antagonize NMDARs directly to cause the circuit dysfunction from abnormal
glutamatergic signaling in anti-NMDAR encephalitis. One suggested mechanism for how
antibody clustering of NMDAR results in their internalization is that upon antibody
binding, NMDARs have a weaker interaction with the EphB2 receptor (Mikasova et al.,
2012), which stabilize and retain NMDARs at synapse (Dalva et al., 2000, 2007). This
effect is strengthened several fold when EphB2Rs are activated by the ligand ephrin-B2.
In fact, exposing neurons to ephrin-B2 along with the pathogenic antibodies partially
rescues the antibody-dependent internalization and loss of NMDARs both in vivo and in
vitro (Mikasova et al., 2012). Measuring the diffusion of single particles using quantum
dot imaging showed that when the NMDAR-EPHB2R complex is disrupted, NMDAR
lateral mobility in the membrane is increased and NMDARs redistribute from being
synaptically clustered to uniformly and diffusely distributed between the synaptic and
extrasynaptic domains. Consistent with the observation that treatment with patient CSF
reduces NMDAR density without affecting other synaptic components (Hughes et al.,
2010), treatment with NMDAR antibodies has no effect on surface diffusion of GluA1,
metabotropic dopamine receptor D1, alpha2 GABAAR subunits, or Kv1.3 (Mikasova et
al., 2012).
Another mechanism for cellular

and tissue damage seen in other
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autoimmune diseases is opsonization of cells with autoantibodies followed by
complement mediated inflammatory cytotoxicity. Muscle biopsies from patients with
myasthenia gravis have revealed extensive deposits of components of the complement
cascade (Engel et al., 1977; Sahashi et al., 1980). Autopsy and in vitro studies have also
linked complement activation with Rasmussen's encephalitis and neuromyelitis optica,
the latter characterized by antibodies to aquaporin-4 (Whitney et al., 1999; Lucchinetti et
al., 2002; Waters et al., 2008). Although antibodies from patients with synaptic
autoimmune encephalitides can fix complement in vitro, biopsies from patient brains do
not contain complement deposits (Martinez-Hernandez et al., 2011). Also, given the
minimal gross tissue damage and the near complete recovery of most patients that are
diagnosed and treated promptly, it is unlikely that complement mediated cell death plays
a major role in clinically relevant pathogenesis.
Antibodies against voltage gated K+ channel associated proteins
Two overlapping syndromes are associated with proteins that are part of the
voltage gated K channel complex (Klein et al., 2013). The CNS dominant disease called
Morvan syndrome is caused by antibodies against the leucine rich glioma activated 1
protein (LGI1; Lai et al., 2010). It is characterized by limbic encephalitis and autonomic
dysfunction, but with neuromyotonia less frequently (Liguori et al., 2001). The PNS
dominant disease, Isaac’s syndrome, is caused by antibodies against contactinassociated protein-like 2 (CASPR2; Shillito et al., 1995; Lancaster et al., 2011), although
around half of anti-CASPR2 encephalitis patients also exhibit encephalitis.
LGI-1 is a secreted protein that has been linked to a pediatric epilepsy disorder
known as autosomal dominant lateral temporal lobe epilepsy (ADLTE; Nobile et al.,
2009). Animal experiments support the role of normal LGI-1 activity in preventing seizure
activity; mice with LGI-1 knocked out

in pyramidal neurons during embryonic
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stages exhibited early-onset seizures that were commonly lethal (Boillot et al., 2014).
LGI-1 when knocked out in rats, mice or zebrafish causes hyperexcitability and seizures
(Fukata et al., 2010; Teng et al., 2010; Yu et al., 2010).
There are several known functions of LGI-1, any or all of which could be disrupted
by the pathogenic anti-LGI-1 antibodies in patients. LGI-1 It integrates into a complex
with presynaptic voltage-gated potassium channel Kv1.1 and prevents its inactivation by
blocking the cytoplasmic regulatory protein Kvbeta1 (Schulte et al., 2006). It has also
been shown to complex with synaptic scaffolding proteins ADAM22 and ADAM23, which
stabilize and retain AMPARs at the synapse. LGI-1 knockout rats had decreased AMPA
mEPSP amplitude in the hippocampus of acute brain slices suggesting that LGI-1
potentiates AMPAR-mediated synaptic transmission (Ohkawa et al., 2013).
In anti-LGI-1 encephalitis, antibodies result in a loss of AMPARs from glutamatergic
synapses. The antibodies disrupt LGI-1 and ADAM22/23 interaction that may destabilize
the machinery that sequesters AMPARs to synaptic membranes. Soluble extracellular
ADAM22 mimicked the effect of anti-LGI-1 antibodies on AMPAR trafficking out of the
synaptic domain. This is similar to the disruption of the interaction between NMDARs
and EphB2Rs by anti-NMDAR antibodies (Mikasova et al., 2012). It would be interesting
to measure the diffusion coefficient of quantum dot labeled AMPARs after exposing the
neuron to anti-LGI-1 antibodies. The role of LGI-1 in maintaining AMPAR levels has
been confirmed in vivo. LGI-1 null mice have reduced AMPARs at synapses. The
ADAM22 complex binds to ADAM23 presynaptically and this is thought to regulate levels
of synaptic AMPAR levels. Changes in AMPAR levels underlie plasticity, global brain
excitability, and homeostatic scaling that maintains the average synaptic gain while
preserving the information encoded in the relative strengths of synaptic inputs onto a
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neuron (Shepherd and Huganir, 2007; Lu et al., 2009; Ohkawa et al., 2013)
Antibodies against GABA receptors
Patients with antibodies against either the ionotropic GABAAβ3 subunit or
metabotropic GABAB receptor B1a subunit typically present with seizures that are
refractory to antiepileptic treatment. Patients with either disease have a higher risk of
mortality typically due to unmitigated status epilepticus (Höftberger et al., 2013; PetitPedrol et al., 2014). The patient presentations are consistent with the known functions of
both ionotropic and metabotropic GABA receptors. Human mutations in either GABAA or
GABAB have been associated with genetic epilepsy syndromes. Mice that are genetic
nulls for either GABAA subunits or GABAB receptors have a lower seizure threshold
(Prosser et al., 2001). Important antiepileptic and anxiolytic drugs such as
benzodiazepines and barbiturates modulate GABAA activity. Similarly, baclofen, a
GABAB antagonist, is used as an anti-spasmodic.
Despite the similarity in presentation and clinical course, the mechanism of
antibody-mediated disruption of the cognate receptor is different in the anti-GABAA and
anti-GABAB encephalitis. Similar to the encephalitides with antibodies against
glutamatergic ionotropic receptors, patient anti-GABAA antibodies reduce both synaptic
GABAA receptors as seen by immunostaining and picrotoxin sensitive IPSCs in cultured
hippocampal neurons. The effects of these antibodies are specific for the cognate
receptors; anti-GABAA antibodies do not affect NMDARs, glutamatergic synaptic
transmission, or the localization or amount of the GABAA synaptic anchoring protein,
gephryn.
In contrast to anti-GABAA receptor antibodies, it is striking that anti-GABAB1
receptor antibodies do not result in a loss of surface GABAB receptors. How then do anti12

GABAB antibodies result in a change in inhibitory tone via GABAB activation that is likely
to underlie the refractory status epilecticus in patients? In live cultured neurons,
application of a GABAB agonist such as baclofen results in a reduction in global synaptic
activity. Anti-GABAB antibodies block this effect. If GABAB1 antibodies do not reduce the
density of GABAB receptors, then they must inactivate or interfere with the target
receptors. One possibility is that the antibodies act as an orthosteric or an allosteric
blocker of GABAB receptors. This would predict that patient antibodies can disrupt
GABAB signaling with an acute application, and the antibody blocking effect should be
dose dependent. Additionally, an allosteric agonist of GABAB1 or an activator of GABAB2
should circumvent the GABAB signaling block by patient antibodies. Another possibility is
that the patient antibodies activate the GABAB receptors and a prolonged incubation with
patient antibodies results in a tonic constitutive GABAB signaling, which then results in
deactivation of receptors. These questions are currently being addressed by studying
the pharmacological properties of anti-GABAB antibodies in both cultured neurons and
heterologous cultured cells that have been transfected to express GABAB receptors
exogenously.

Homeostatic plasticity in response to antibody-mediated decrease of receptor
levels
Homeostatic plasticity is important for maintaining the stability of neuronal network
activity in the face of potentially destabilizing changes in the strengths of individual
synapses. Compensatory mechanisms at the cellular and synaptic level have been
shown to occur in autoimmune disorders of the nervous system in humans and in
experimental model systems. Studies from mouse models of myasthenia gravis and
patients' tissue have shown an enhanced rate of synthesis of AChRs and increased
expression levels of AChR α, β, δ,

and ε subunits, as well as increased
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ACh release upon stimulation (Wilson et al., 1983; Guyon et al., 1994, 1998; Plomp et
al., 1995). Similarly, in the CNS, Purkinje cells treated with IgG from patients with
Lambert-Eaton syndrome show a loss of P/Q-type voltage gated calcium channel
currents and a concomitant increase in R-type currents (Pinto et al., 1998). The NMDAR
hypofunction in anti-NMDAR encephalitis led us to the question of whether patient
antibody treatment can induce homeostatic changes in cultured neurons.
It is well known that after pharmacological blockade of glutamate receptors,
cultured neurons compensate by changing both excitatory and inhibitory synaptic
strength. Several studies have shown that, after 48 hours of NMDAR or AMPAR
blockade, mEPSC amplitude is enhanced (Turrigiano et al., 1998; Sutton et al., 2006).
Treatment of cultured neurons with antibodies from patients with anti-NMDAR
encephalitis results in a decrease in glutamatergic transmission via NMDA receptors.
Therefore it is plausible that neurons compensate for a loss of functional NMDA
receptors by reducing inhibitory synaptic transmission or by increasing NMDAR and
AMPAR expression. Treatment of cultured neurons does not increase expression of
NMDARs or AMPARs, but result in a decrease in inhibitory synapse density visualized
as colocalizing GABAA and VGAT clusters (Moscato et al., 2014).
Similarly, in anti-AMPAR encephalitis, antibody treated neurons compensate for the
loss of AMPAR conductance by decreasing GABAAR mIPSC amplitude. In addition to
changes at the synapse, treatment with anti-AMPAR antibodies increases intrinsic
neuronal excitability (Peng et al., 2014). While the average action potential firing
frequency was unaffected, antibody treatment changed the pattern of firing as evidenced
by a decrease in inter-spike interval. These compensatory changes are consistent with
numerous observations that pyramidal neurons tend to homeostatically maintain firing
rate in response to chronic inactivity

(Turrigiano et al., 1998; Burrone et al.,
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2002). This may explain why despite reducing excitatory synaptic transmission via
glutamate receptors, patient antibodies are capable of inducing synaptic and neuronal
changes that contribute to the short-term memory loss and seizures observed in patients
with anti-AMPAR encephalitis.

In vivo effects of anti-receptor antibodies on circuits and behavior
Patient antibodies disrupt their cognate antigens at synapses in cell culture. This
synaptic dysfunction and the accompanying homeostatic changes are likely to underlie
the circuit malfunction and psychologic and neurologic deficits in patients. To test
whether anti-NMDAR antibodies from patients can disrupt NMDAR-dependent circuit
properties in vivo, Zhang et al. (2012) tested the effect of a short treatment with patient
antibodies on LTP induction at Schaffer collateral–CA1 synapses in rodent acute
hippocampal slices. Genetic and pharmacological block of NMDAR blocks induction of
LTP at these synapses although their activity is not necessary for maintenance of LTP.
In slices treated with anti-NMDAR antibodies for 15 minutes, the induction of LTP by
theta burst stimulation was suppressed (Fig. 4C-D; Zhang et al., 2012). This suppression
was not present when slices were treated with patient CSF that had antibodies adsorbed
on HEK cells overexpressing NMDAR. LTP in hippocampal synapses is a leading
candidate for the circuit property that encodes place memory and loss of LTP induction
in the hippocampus of rodents after exposure to patient antibodies may disrupt memory
in awake behaving animals.
In a large rodent study, Planaguma et al. (2014) generated a passive immune
transfer model of anti-NMDAR encephalitis to test the effects of patient antibody infusion
on animal behavior. Using osmotic pumps, they infused a dialyzed mixture of CSF from
several patients or controls into the cerebral ventricles of mice for 14 days. The pumps
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were removed after 14 days to enable studying recovery from a chronic exposure to
pathogenic antibodies from patients. A dramatic loss of novel object memory and
anhedonia in the mice with chronic infusion of patient antibodies was observed over 14
days of infusion. However, by day 18 (day 4 after cessation of infusion), both the
memory deficits and anhedonia had returned to control levels (Fig. 4E). The behavioral
deficits correlated with a NMDAR levels in the brain, which also decreased during the
14-day infusion and recovered completely by day 21 (Planagumà et al., 2014). This
study demonstrates the pathogenic potential of antibodies present in patients with antiNMDAR encephalitis. It also establishes the relationship between the effects of
pathogenic antibody on synapse and circuit function, and the changes in behavior,
memory and cognition that are hallmarks anti-NMDAR encephalitis.
Recent translational studies have begun to shed light on whole brain activity during
anti-NMDAR or anti-AMPAR encephalitis. Diffusion tensor MRI in anti-NMDAR patients
shows decreased functional connectivity between the two hippocampi and extensive
white matter changes that correlates with disease severity (Finke et al., 2013). Imaging
studies in anti-AMPAR encephalitis patients have identified hypermetabolism in the
limbic area on 18-F-FDG PET, which correlates with severity of clinical course (Spatola
et al., 2014). EEG studies identified a characteristic electrographic pattern in antiNMDAR encephalitis known as “extreme delta brush”, characterized by rhythmic delta
activity at 1-3 Hz with superimposed 20-30 Hz bursts superimposed on each delta wave
(Schmitt et al., 2012; Armangue et al., 2013). The clinical significance of the extreme
delta brush pattern is unclear, but reflects widespread cortical and subcortical network
dysfunction.

Mechanisms of autoimmunity
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In the majority of autoimmune encephalitides, patients are much more likely than
normal to have an associated neoplasm. These encephalitides were initially classified as
paraneoplastic syndromes. The associated tumors are often dedifferentiated tissues that
express many neuronal proteins. Among patients with teratomas, the ones with a
comorbid NMDAR encephalitis were more likely than neurologically intact patients to
have dysplastic CNS neurons in teratomas that express NMDARs (Day et al., 2014).
The tumor microenvironment along with the inappropriate expression of neuronal
proteins in non-neuronal contexts may contribute to the breakdown of immune tolerance
(Maueröder et al., 2014). Another possibility is that mutant genes in tumors produce
proteins are structurally different enough from the wild type protein to escape immune
tolerance and induce an immune response that is cross-reactive to both the mutant and
wild type gene product (Engelhorn et al., 2006). A well-studied example is scleroderma,
an autoimmune connective tissue disease, in which a subset of patients that have
autoantibodies to RNA polymerase III are more likely to have cancer (Shah et al., 2010).
The cancers in these scleroderma patients harbor missense mutations in the gene
encoding for RNA polymerase III, POLR3A, and the T cells in these patient that were
reactive to mutant RNA polymerase cross-reacted with the wild type form of the protein
(Joseph et al., 2014).
Not all patients with autoimmune encephalitis have a co-morbid neoplasm. It is
possible, but unproved, that an immune response elicited by the tumor and the
subsequent antibody synthesis decreases the size or eliminates the tumor via antibody
binding and complement mediated cytotoxicity. Thus, at the time of diagnosis, antibodies
are present, but no tumor is detected.
A genetic predisposition to autoimmunity may contribute to sensitizing the immune
system against essential synaptic

proteins. Another evidence for the
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association between tumor and synaptic autoimmunity is that higher titers correlated with
poor outcome and presence of teratoma. In the case of anti-NMDAR encephalitis, the
presence of a tumor is correlated with more severe disease and higher titers.
Conversely, in patients with tumors, excision of the tumor was one of the most effective
treatment modality (Gresa-Arribas et al., 2014).
Identification of the epitope of pathogenic antibodies in anti-NMDA, anti-AMPAR,
anti-CASPR2 and anti-GABAB1 encephalitides raise an intriguing possibility that regions
of these synaptic proteins may be inherently immunogenic. In all these diseases, the
identified epitope is nearly identical regardless of the age, sex, tumor status, or disease
severity of patients (Gleichman et al., 2012). Moreover, in anti-NMDAR encephalitis, the
epitope remained constant over disease progression (Gresa-Arribas et al., 2014).
Domain swapping and point mutation experiments identified the N368/G369 region of
the LIVBP domain of NMDAR1 to be the minimal epitope necessary for antibody binding
(Gleichman et al., 2012).
Molecular mimicry or the cross reactivity of antibodies against infectious epitopes
with normal host proteins can occur if the epitopes are sufficiently similar. Guillain-Barré
syndrome (GBS), an immune mediated peripheral neuropathy affecting axons and
myelin sheaths is a classic example of an autoimmune neurologic disease that is known
to arise from molecular mimicry (Hahn, 1998; Hughes and Cornblath, 2005). The
disorder is frequently preceded by an infection, often by Campylobacter jejuni (Rees et
al., 1995; McCarthy and Giesecke, 2001). Patients' serum antibodies react with
peripheral nerve gangliosides as well as lipooligosaccharide from Campylobacter
jejuni (Oomes et al., 1995; Yuki et al., 2004). Similarly, a syndrome known as
Sydenham's chorea is characterized by abnormal movements, hypotonia, and
neuropsychiatric symptoms, and

characteristically occurs after an
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infection by group A streptococci (Marques-Dias et al., 1997; Kirvan et al., 2006). Like in
GBS, antibodies from patients with Sydenham's chorea react with gangliosides
expressed in the basal ganglia and cross-react with group A streptococcal N-acetylglucosamine (Bronze and Dale, 1993; Kirvan et al., 2003). Patients with SLE, a
multisystem autoimmune disease, can harbor antibodies to double stranded DNA that
also cross react with a single epitope present in the extracellular region of NR2A and
NR2B of the NMDAR (DeGiorgio et al., 2001; Kowal et al., 2006). Cross reacting antidouble stranded DNA antibodies are more prevalent in SLE patients with
neuropsychiatric symptoms, but can also be seen in neurologically normal patients.

The source and brain access of autoantibodies
Two different, but not mutually exclusive, sources of pathogenic antibodies can
synthesis of antibodies within the intrathecal space by plasma cells derived from antineuronal targeted B cells that translated across the blood brain barrier and matured
within the intrathecal space or the antibodies are synthesized peripherally and cross the
blood brain barrier that has been pathologically disrupted.
Antibodies that are synthesized in peripheral lymph nodes and serum can cross the
blood brain barrier passively and down their concentration gradient if the barrier
becomes more permeable in disease. There are several methods for experimentally
increasing BBB permeability to test the effect of peripherally generated antibodies on
CNS functions including focal ultrasound (Kinoshita et al., 2006), hypertonic solute
(Neuwelt et al., 1988) and lipopolysaccharide (Xiao and Jan, 2009). More physiologically
relevant models of BBB disruption include peripheral inflammation (Rabchevsky et al.,
1999; Huber et al., 2001), acute stress (Esposito et al., 2002), and epinephrine (Huerta
et al., 2006). At least in rodent models, crossing of serum protein including antibodies
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has been shown to increase after inducing a “leaky” blood brain barrier experimentally.
Iodinated antibodies injected into rats were detected in the brain following osmotic
opening of the BBB (Neuwelt et al., 1988). Kinoshita et al. showed that focal sonication
caused BBB disruption allowing intravenously injected dopamine receptor antibodies to
enter the brain and bind to antigen at sites of barrier breakdown (Kinoshita et al., 2006).
A clinical observation that is consistent with the possibility of peripheral antibody
synthesis with transudation across a disrupted blood brain barrier is that many patients
with autoimmune encephalitis report a history of flu-like prodromal symptoms or
demonstrated viral infection prior to presenting with neuropsychiatric syndrome of
autoimmune encephalitis (Dalmau et al., 2004). It is possible that a systemic
inflammation induced by a bacterial or viral infection transiently disrupts the BBB, and
allows antibodies that were already present in the serum to enter the intrathecal space.
Memory B-cells that are able to cross a normal BBB will undergo re-stimulation,
antigen-driven affinity maturation, clonal expansion, and differentiation into NMDAR
antibody-secreting plasma cells. This mechanism, which occurs in other autoimmune
diseases such as multiple sclerosis (Hauser et al., 2008), would explain the detection of
intrathecal synthesis of antibodies in most patients with anti-NMDAR encephalitis.
Clinical pathology investigations of CSF from autoimmune encephalitis patients support
intrathecal synthesis of pathogenic antibodies. These patients often have an increased
ratio of CSF IgG to serum IgG concentration. This could result from the intrathecal space
being the source of antibodies and the peripheral space being the sink or anti-neuronal
antibodies present in serum when given access to neuronal tissue get sequestered close
to the neuronal tissue. Additionally, protein electrophoretic analyses of the CSF from
autoimmune encephalitis patients demonstrates multiple distinct bands of IgG that are
absent in serum (oligoclonal bands),

supporting the presence of plasma cell
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clones within the thecal space that that are absent in serum and thus may have matured
after their progenitor B cells extravasated intrathecally (Dalmau et al., 2008).
The relative lack of efficacy of strategies for treating autoimmune encephalitis by
depleting serum IgG (IVIg, plasma exchange) is another piece of evidence to support the
presence of the source of pathogenic antibodies intrathecally. IVIg and plasmapharesis
alone are no longer considered standard of care or appropriate first line treatment for
autoimmune encephalitis (Martinez-Hernandez et al., 2011). Patients that do not
respond to IVIg or plasma exchange often improve with immunomodulatory drugs that
affect immune cells such cyclophosphamide and rituximab. Also, a retrospective study of
titers and disease progression showed that higher titers of antibodies in CSF but not in
serum correlated with poor neurologic outcome (Gresa-Arribas et al., 2014). Additionally,
relapses of neuropsychiatric decline correlated more with CSF titer change than serum
titer.
There is also direct evidence for the presence of CD138+ plasma cells in
perivascular, interstitial and Virchow-Robin spaces in brain biopsies from patients (Fig.
5). Biopsies in 14 cases and autopsy of three patients showed microgliosis, occasional
inflammatory B-cell and plasma cell infiltrates, and very rare T-cell infiltrates (MartinezHernandez et al., 2011), in contrast to other paraneoplastic syndromes in which only
cytotoxic T-cell infiltrates are prominent (Stein-Wexler et al., 2005). These lymphocytes
may be recruited by chemokines secreted by monocytes and microglia. Patients have a
higher level of B-cell–attracting C-X-C motif chemokine 13 (CXCL13) in their CSF
compared to controls but there was no difference in serum (Leypoldt et al., 2014).
Moreover, anti-NMDAR patients from whom brain biopsy samples are available showed
infiltration of monocytes and microglia that express CXCL13 (Fig. 5C). This suggests
that despite being an immune

privileged organ, the intrathecal space
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of autoimmune encephalitis patients displays all the hallmarks of an organ with an
adaptive immune system response: antigen presenting cells secreting chemokines,
extravasation of immature lymphocytes, and mature plasma cells producing antineuronal antibodies.

Effects of synaptic receptor antibodies related to neurologic symptoms
Glutamate binding to NMDARs and AMPARs is crucial for synaptic transmission
and plasticity. Pharmacological blockade or genetic reduction of NMDARs or AMPARs
has been shown to alter measures of learning and memory and other behaviors in
animal models (Mohn et al., 1999; Kapur and Seeman, 2002; Schmitt et al., 2007; Labrie
et al., 2008). The balance between excitatory and inhibitory synaptic inputs is also
altered, and this has been shown to affect circuit function and behavior (Prange et al.,
2004; Epsztein et al., 2006; Kehrer et al., 2008). In addition, NMDA (Olney et al., 1999;
Coyle and Tsai, 2003; Stahl, 2007) and/or AMPA (Wiedholz et al., 2008; Zavitsanou et
al., 2008) receptor hypofunction has been proposed to be part of the pathophysiological
mechanisms underlying schizophrenia.
It is interesting to consider why patients with anti-NMDAR antibodies develop a
complex syndrome that includes psychosis, learning and memory dysfunction, abnormal
movements, autonomic instability and frequent hypoventilation, while those with AMPAR
antibodies preferentially develop psychiatric and amnestic symptoms. Studies using
genetic deletion of NMDAR or AMPAR subunits in mouse models provide some insight
into this issue. While NR1 knockout mice die shortly after birth due hypoventilation (Li et
al., 1994), mice with spatially restricted NR1 deletion can survive into adulthood
(Nakazawa et al., 2004). CA1-specific NR1 knockouts have impaired spatial and
temporal memory and a loss of CA1 LTP (Tsien et al., 1996). Mice with an inducible,
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reversible knockout of NR1 in forebrain show impairment in the maintenance of longterm memory if NR1 expression is turned off during the memory storage phase.
In addition to memory deficits, targeted manipulation of NR1 expression can result
in schizophrenia-like symptoms. Hypomorphic expression of NR1 leads to increased
stereotypic behavior and decreased sociability, while early postnatal loss of NR1 in a
subset of cortical and hippocampal interneurons results in decreased pre-pulse inhibition
and increased social isolation-induced anxiety (Mohn et al., 1999; Belforte et al., 2010).
Moreover, subanesthetic doses of NMDAR blockers such as phencyclidine and
ketamine are psychotomimetic, and they recapitulate many of the positive and negative
signs of schizophrenia in humans and rodents as well as repetitive orofacial movements,
autonomic instability and seizures (Luby et al., 1962; Krystal et al., 1994; Lahti, 2001;
Krystal, 2002).The remarkable similarity between these phenotypes, the effect of
patients' antibodies resulting in a dramatic decrease of synaptic NMDAR clusters and
function, and the reduced levels of NMDARs in autopsied patients, support an antibodymediated pathogenesis of anti-NMDAR encephalitis, and strengthen the NMDAR
hypofunction hypothesis of schizophrenia (Belforte et al., 2010).
The consequences of loss of AMPAR expression have also been studied in mouse
models. Spatial learning and memory are largely unaffected in GluR1 knockout mice
despite the fact that LTP is reduced in CA1 and CA3 (Zamanillo, 1999) and working
memory is diminished (Reisel et al., 2002; Sanderson et al., 2007). GluR2 knockout
mice show reduced exploration and impaired motor coordination. In these animals,
AMPAR mediated synaptic transmission is reduced, but LTP is enhanced (Jia et al.,
1996; Gerlai et al., 1998). GluR2 knockout mice also have increased cell death
(Feldmeyer et al., 1999; Oguro et al., 1999), possibly due to excitotoxicity related to
increased, compensatory insertion of

GluR1 homomeric AMPARs. While
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AMPAR subunit knockout mice have not provided a satisfying explanation for the role of
AMPARs in synaptic plasticity related to learning and memory, the fact that patients with
AMPAR antibodies have short-term learning and memory deficits argues that further
studies at the circuit and behavioral levels are warranted.
GABAB1 receptor knockout mice display a variety of neurologic and behavioral
abnormalities, including spontaneous seizures, enhanced anxiety, hyperactivity,
hyperalgesia, and impaired memory (Prosser et al., 2001) suggesting dysfunction of the
limbic system. Consistent with these experimental data, patients with antiGABAB1 receptor antibodies present with an encephalitis that associates with early and
prominent seizures, confusion, agitation, behavioral problems and severe short-term
memory deficit along with MRI abnormalities predominantly involving the hippocampi.
Interestingly, both GABAB1 receptor knock out mice and mice treated with a
GABAB1 receptor antagonist, CGP56423A, exhibit antidepressant-like behavior in a
forced swim test and a learned helplessness paradigm (Nakagawa et al., 1999;
Mombereau et al., 2004), suggesting that GABA signaling may have disparate effects on
different aspects of mood such as depression and anxiety. Combined with animal
studies, these patients can provide rich insight into the role of GABAB1 receptor signaling
in memory, behavior, and cognition.

Conclusion
Each of the clinical syndromes under the umbrella of autoimmune encephalitis is an
opportunity to not only understand the mechanism by which the human body fails to
distinguish self from non-self but also how autoantibodies cause CNS disease. The
basic science and translational work on the unique aspects on each of the autoimmune
encephalitides underscores the fact that despite a failure in immunotolerance, cellular
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and humoral factors can disrupt their target antigen in distinct ways.
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Figures

Fig 1. Flowchart of identifying a cluster of autoimmune encephalitis patients, identifying
the target antigen, and laboratory

characterization.
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Figure 2. Process of characterization, antigen immunoprecipitation, and development of
diagnostic tools. (A) Immunohistochemistry of rat brain section stained with patient CSF
(anti-NMDA receptor encephalitis; Dalmau et al., 2007). Scale bar = 1mm. (B)
Dissociated rat hippocampal neurons maintained in vitro and incubated (live,
nonpermeabilized) with patient CSF. Note the binding of of patient's antibodies with
clusters of cell surface antigens; scale bar = 10 μm. (C) Precipitation of these antigens
using two patients’ CSF antibodies is shown in a gel in which proteins are visualized with
EZBlue. Note that patients’ antibodies (P1, P2) precipitated a single band at ∼100 kDa;
this band is not seen in the precipitate generated with CSF from a control individual (N).
Analysis of the 100 kDa band by mass spectrometry demonstrated sequences derived
from GluR1/GluR2 subunits of the AMPA receptor. The ∼50 kDa band across all
samples corresponds to IgG. Transfer of the proteins to nitro‐cellulose and Western blot
with GluR1 and GluR2 antibodies confirmed that the 100 kDa band contained both
GluR1 and GluR2 subunits (not shown). (D-F) Further validation of the antigen was done
in heterologous cells expressing GluR1/2, showing reactivity with patient's antibodies (D,
green), a commercial monoclonal GluR1 antibody (E, red), and merged (F, yellow).
Scale bar = 10 um. Figure panels from Lai et al., 2009.
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Figure 3. Synaptic effects of antibodies from patients with anti-NMDAR encephalitis. (A–
C) AMPA and NMDA receptors are localized in the postsynaptic membrane and are
clustered at the postsynaptic density. (A) Patient antibodies bind selectively to synaptic
and extrasynaptic NMDA receptors, and this binding leads to receptor cross-linking (B).
Cross-linked and clustered NMDA receptors are internalized, resulting in a decrease of
surface NMDA receptors while other synaptic components, such as postsynaptic AMPA
receptor clusters and PSD-95, as well as presynaptic terminals, dendrite branches,
dendritic spines and cell viability, are unaffected (C). Panels A-C adapted from Moscato
et al 2010. (D–E) Rodent cultured neurons treated within patient's CSF results in
internalization of antibody bound NMDA receptors. After treatment with patient CSF for
1h (D) or 12h (E), surface NMDA receptors were stained using an anti-human IgG
secondary antibody conjugated to Alexa 488 on live cultured neurons. After fixing and
permeabalization, an anti-human IgG secondary antibody conjugated to Alexa 594 is
used to stain the internalized antibody bound fraction of NMDA receptors.
Counterstaining with a commercial antibody labeled the total pool of NMDA receptors.
Scale bar = 1 um. (F–G) Whole-cell patch recordings of miniature excitatory
postsynaptic currents (mEPSCs) that consist of a fast AMPA receptor–mediated
component and a slower later component mediated by NMDA receptors that is APV
sensitive. Compared with neurons without patient antibody mediated internalization,
those treated with CSF from a patient with NMDA receptor antibodies show a loss of the
APV-sensitive NMDA receptor component G (Hughes et al., 2010). (H) Quantification of
surface and internalized NMDARs following treatment. Surface NMDAR density was
significantly decreased after 12 hours of patient CSF treatment compared with patient
antibody-derived F(ab) fragments after which surface levels reached a plateau. This was
paralleled by an increase over time in

the density of internalized NMDARs.
30

Panels D-H adapted from Moscato et al., 2014.
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Figure 4. Infusion of CSF from patients with NMDAR antibodies into rodent brains
reduces synaptic NMDA receptors and results in deficits circuit plasticity, memory and
behavior (A-B) Three-dimensional projection and analysis of the density synaptic
clusters of NMDA receptors (defined as NMDAR clusters colocalized with PSD95) in
CA3 region of hippocampus. (C-D) Suppression of LTP by CSF obtained from an antiNMDAR encephalitis patient (Zhang et al., 2011). (C) Superimposed field EPSPs
(fEPSPs) recorded at Schaffer colateral-CA1 synapses immediately before (black) and
30 min after TBS (red). For assessment of the magnitude of LTP, the initial slope of
post-tetanic fEPSP (red) was expressed as percent of the pre-tetanic slope (black). The
slope was measured as indicated in the middle panel (dotted lines). Scale bars: 2 ms
and 0.5 mV. (D) Averaged LTP time course. The slope of fEPSPs was expressed as
percent of those recorded immediately before TBS. The lines represent data from the
artificial CSF control (solid line with filled circles), the non-encephalitis control (solid line
with open circles), the herpes simplex virus encephalitis control (HSV; chain line with
open triangles) and the NMDAR antibody positive case (chain line with filled triangles).
(E) Infusion of CSF from patients with NMDAR antibodies causes deficits in memory,
anhedonia and depressive-like behavior. Novel object recognition index in open field is
reduced in animals treated with patients’ CSF (grey circles) but not control CSF (white
circles) after 14 days of chronic infusion. The patient CSF infused animals recover their
novel object memory 11 days after the cessation of infusion (day 25 post surgery). A
higher novel object Index indicates better object recognition memory. Figure adapted
from Planaguma et al., 2014 and Zhang et al., 2011.
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Figure 5. Brain biopsy of a patient with anti-NMDAR encephalitis showing perivascular
lymphocytic and monocytic Infiltrates. (A) In Virchow-Robin spaces, CD138+ plasma
cells are in perivascular regions (arrows) and along the tissue surface (arrowheads) that
delineates spaces containing CSF and small vessels (v). The plasma cells/plasmablasts
indicated with arrows are amplified in the inset in K. Scale bars = 20 m. (B-C) Monocytic
infiltrates expressing CXCL13, a B-cell attracting chemokine (B, arrow heads). Infiltrates
were mainly composed of monocytes and macrophages (B, arrow heads indicate CD68
expressing monocytes and macrophages). Scale bar = 14 μm. Figure adapted from
Stein-Wexler et al., 2005 and Leypoldt et al., 2014.
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Abstract
Patients with antibodies to the metabotropic gamma-aminobutyric acid receptor
type B (GABAB) develop severe intractable seizures, but little is known about the
underlying pathophysiological mechanisms. Using deletion mapping and expression in
heterologous cells, we show that patient anti-GABAB receptor antibodies bind to
alternatively spliced Sushi domains that is present in the presynaptically localized
GABAB1a isoform. In contrast to anti-NMDAR antibodies from patients, GABAB receptors
autoantibodies did not decrease in surface GABABRs or their internalization. Treating
neurons with GABAB receptors autoantibodies for as little as 30 minutes blocked the
activation of GABAB receptors by baclofen in an autoantibody titer-dependent manner.
Autoantibody-bound GABABRs are still signaling competent, however, because baclofen
block was circumvented by directly activating GABAB2 with a selective agonist,
CGP7930. Thus, patient GABAB receptor autoantibodies are selective GABAB1
antagonists that may contribute to seizures by interfering with GABA-mediated inhibition.
Brain penetrant GABAB2 agonists may be useful to treat intractable seizures in antiGABABR encephalitis patients.

Introduction
A growing family of autoimmune neurological diseases defined by pathogenic
antibodies to neuronal cell surface proteins has been recognized over the last decade
(Leypoldt et al., 2014). These diseases typically cause profound neuropsychiatric
disability, and may be fatal (Vitaliani et al., 2005; Dalmau et al., 2008; Finke et al., 2012;
Petit-Pedrol et al., 2014), but most patients improve markedly with immunosuppression,
and many patients recover

(Iadisernia et al., 2012; Gresa-Arribas
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et al., 2014). Some of these disorders target important synaptic proteins including the
ionotropic glutamate receptors, N-Methyl D-Aspartate receptor (NMDAR, Sansing et al.,
2007; Dalmau et al., 2008) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR, Lai et al., 2009), the glycine receptor, the ionotropic gammaaminobutyric acid receptor type A (GABAAR, Petit-Pedrol et al., 2014) and the
metabotropic gamma-aminobutyric acid receptor type B receptor (GABABR, Lancaster et
al., 2010). The neuropsychiatric manifestations of these autoimmune encephalitides are
similar to those caused by the genetic or pharmacologic disruption of the corresponding
receptors in animal models and in human genetic diseases (Prosser et al., 2001; Brown
et al., 2003). The specificity of the autoantibodies for receptor subunits, and often
dominant epitopes of these proteins, is exquisite (Gleichman et al., 2012, 2014). While
studies of the effects of patient antibodies on neurons, synapses, circuits, and behavior
have begun to provide important insights into the pathophysiologic etiology of patient
symptoms, many questions remain.
The cellular effects mediated by NMDAR and AMPAR antibodies have been
studied in detail (Lai et al., 2009; Hughes et al., 2010; Moscato et al., 2014; Peng et al.,
2014). These antibodies do not directly inhibit receptor function. Rather, NMDAR and
AMPAR autoantibodies cross-link the cognate synaptic receptors on the surface of
cultured neurons and result in a selective internalization of the target without disrupting
other synaptic components or injurying neurons (Hughes et al., 2010; Moscato et al.,
2010; Peng et al., 2014). Chronic perfusion of NMDAR antibodies into the cerebrospinal
fluid (CSF) of rodents also decreases NMDA receptors after 14 days (Planagumà et al.,
2014). This passive transfer of autoimmunity in mice results in anhedonia and
diminished spatial memory. These effects are reversible in both in vivo and in vitro
model systems (Moscato et al., 2010;

Planagumà et al., 2014). Thus, these
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mechanisms may underlie the neurological and psychiatric manifestations of these forms
of autoimmune encephalitis, and account for recovery of many patients with immune
therapy aimed at lowering antibody titer.
Antibodies to the extracellular domain of B1 subunit of the metabotropic GABAB
receptor (GABAB1) have been have been identified in a subset of patients with
autoimmune limbic encephalitis (15, 10, and 20 patients in Lancaster et al., 2010;
Höftberger et al., 2013; Dogan Onugoren et al., 2014, respectively). These patients
typically present with subacute seizures that are resistant to treatment, along with
confusion, memory loss and behavioral problems. Nearly half the patients have a comorbid small cell lung cancer, and many patients improve with immunosuppression.
Other reports have confirmed this association of antibodies to GABAB1 with encephalitis,
severe seizures, and small cell lung cancers (Lancaster et al., 2010). GABAB1 may be
the most common antigen in patients with small cell lung cancer and autoimmune
encephalitis.
GABAB receptors are G-protein coupled receptors (GPCRs) for the inhibitory
neurotransmitter GABA (Kaupmann et al., 1997). They are obligate heterodimers of
GABAB1, which binds GABA, and GABAB2, which activates intracellular G-protein
mediated signaling (Robbins et al., 2001; Schwenk et al., 2010). The GABAB1 subunit
has two distinct isoforms with different localization and function (Vigot et al., 2006).
GABAB1a is found in presynaptic receptors, which can decrease in synaptic vesicle
release by inhibition of presynaptic calcium influx (Harrison, 1990). The GABAB1b
subunit is found in post-synaptic receptors (Hannan et al., 2012), which can reduce
excitability by the opening of G-protein coupled inwardly rectifying K+ channels (GIRK,
Lüscher et al., 1997). Hypoactivity of GABAB signaling is implicated in epilepsy,
spasticity, anxiety, addiction, autism

and pain. GABAB1 null mice have
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decreased sensorimotor gating, spontaneous seizures, hyperlocomotion and memory
impairment (Prosser et al., 2001). Baclofen, a selective GABAB agonist, is used
routinely to treat spasticity in patients.
Here, we describe the target epitope of human GABAB1 autoantibodies and
demonstrate that these antibodies preferentially target the GABAB1a isoform of the
receptor. The cellular effects of anti-GABAB1a antibodies on cultured hippocampal
neurons are strikingly different from those of antibodies to ionotropic glutamate
receptors. GABAB1 antibodies do not result in internalization of surface GABAB
receptors. Rather, patient GABAB1 antibodies prevent activation of the GABAB1 subunit
by the agonist baclofen, without affecting the ability of the GABAB2 subunit to induce Gprotein mediated signaling. GABAB1 receptor antagonism may account for the severe
and intractable seizures that are prominent in patients with CSF GABAB1 antibodies.
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Materials and Methods
Patients and human samples
Cerebrospinal fluid and serum were obtained from patients with well-characterized
clinical manifestations of anti-GABAB receptor encephalitis. Control samples were
obtained from patients undergoing CSF screening for various disorders not associated
with antibodies against known neuronal antigens. Control CSF used in this study was
confirmed to not have any anti-neuronal antibodies using the methods described below.
The clinical characteristics of patients with GABAB antibodies whose CSF was used in
this study have been described previously (Lancaster et al., 2010; Höftberger et al.,
2013).
Primary neuron cell culture and treatment
Hippocampi from embryonic day 18 rat pups were subjected to proteolytic digestion
and mechanical disruption as previously described (Hughes et al., 2010). Briefly,
dissociated cells were plated onto poly-L-lysine coated 15 mm coverslips at a density of
25,000 cells/cm2 and incubated in Neurobasal medium. Neurons were treated on days
in vitro (div) 17 – 21 with CSF from patients or controls at dilutions specified in the figure
legends.
Antibodies
The following antibodies were used at the indicated dilutions for Western blots
(WB), HEK293 cells (H) or dissociated neurons (N): GluN1 (rabbit, WB 1:1000, Millipore
AB9864R), GluA1 (rabbit, WB 1:200, Millipore AB1504), GABAB1Rs (guinea pig, WB
1:200 N 1:500 H 1:2000, Millipore AB2256), GABAARβ2/3 (mouse, WB 1:200, Millipore
05-474), and β-actin (chicken, WB 1:1000, Abcam ab13822), myc tag (mouse, 1:1000,
Sigma 9E10). Omission of primary antibodies was used as a control for each of the
secondary antibodies, which were

raised in goat and conjugated to
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various Alexa Fluor or Dylight dyes (Jackson Immunoresearch).
Immunostaining and microscopy
Hippocampal neurons on coverslips were fixed and stained as previously described
(Hughes et al., 2010). Briefly, neurons were fixed with freshly prepared 4%
paraformaldehyde/4% sucrose for 10 min, blocked in 5% goat normal serum/ 0.1%
Triton X-100 for 1 hour and washed in phosphate buffered saline (PBS) three times for 5
min each, incubated with primary antibodies diluted in block overnight at 4oC and
washed, then incubated in secondary antibodies for 1-2 hours at room temperature and
washed. Coverslips were mounted, sealed and imaged on a confocal microscope (TCS
SP5, Leica, Wetzlar, Germany).
To selectively label internalized human IgG, neurons were incubated with patient
CSF (1:50), followed by incubation with goat anti-human secondary antibody conjugated
to Alexa 488 (1:100). After 1-2 hours, neurons were fixed, permeabalized, and stained
with goat anti-human secondary antibody conjugated to Alexa 594 to selectively label
human IgG bound internalized receptors.
Images acquired on the confocal microscope were analyzed using custom-written
ImageJ macros as previously described (Hughes et al., 2010). Briefly, images were
background corrected by subtracting a Gaussian blur of the image, followed by adaptive
thresholding and cluster detection to produce a binary mask of clusters (Bergsman et al.,
2006).
Immunohistochemical staining of brain sections was carried out as described
previously (Gable et al., 2009). Briefly, mouse brain hemisections were immersion fixed
in freshly prepared 4% paraformaldehyde for 2 hours and then cryoprotected in 30%
sucrose until equilibrated. Snap frozen brains were saggitally sectioned at 10 um, and
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mounted on glass slides. Sections were immersed in 0.3% hydrogen peroxide for 10 min
and then washed, blocked in 5% goat normal serum, incubated with patient CSF (1:50)
overnight at 4oC and washed, then incubated with biotinylated goat anti-human IgG
secondary antibody (1:2000) and washed, incubated with avidin-biotin-peroxidase
complex (ABC kit, Vector Labs) for 1 hour and washed. The sections were incubated
with diaminobenzidine (DAB Eqv, Vector Labs) for 5 - 15 mins; the reaction was stopped
when a section not incubated with patient CSF begins developing staining. The sections
were washed, counterstained with hematoxylin, dehydrated in ethanol, cleared in
Citrasolv (Fisher) and mounted with Permount (Sigma).
Biotinylation of surface proteins and analysis by Western blot
Five coverslips of dissociated hippocampal neurons were treated with patient or
control CSF (1:25) for 24 hours and prepared for protein extraction as previously
described (Hughes et al., 2010). Briefly, neurons were washed in PBS, incubated with
1mg/ml sulfo-NHS-biotin (Thermo Fisher Scientific) for 30 min at 4oC, lysed in RIPA
buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris-HCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, pH 7.4, supplemented with 1:500 protease inhibitor mixture III
(Calbiochem) for 1 h at 4°C, and centrifuged at 4000g for 20 minutes. An aliquot of the
supernatant was assayed for total protein. The biotinylated fraction of proteins in the
remaining supernatant was adsorbed onto avidin-linked agarose beads (Immobilized
Monomeric Avidin; Thermo Fisher Scientific) overnight at 4°C, beads precipitated, and
the supernatant was saved to assay proteins in the intracellular fraction. Protein bound
to beads was eluted to assay proteins in the surface fraction. Protein samples were
denatured and reduced by boiling in Laemmli buffer, separated on a 4-15% gradient
SDS-PAGE gel and transferred to nitrocellulose membranes. The surface, intracellular
and total fractions were probed with

primary antibodies. Membranes were
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incubated with alkaline phosphatase (AP)-conjugated goat secondary antibodies
(1:3000, Cell Signaling), and signals were visualized using Western-Star
chemiluminescent detection system (Applied Biosystems).
Heterologous cell transfections and cDNA constructs
GABAB1a and GABAB2 cDNAs were the gift of Dr. Steve Moss (Calver et al.,
2000). mCD8 cDNA was a generous gift from Dr. Steve Scherer. All deletion constructs
were generated with the Quickchange kit following a modification of the manufacturer’s
protocol.
HEK293 cells (ATCC) were grown on Poly-D-lysine coated coverslips in 24 well
plates in DMEM supplemented with 5% fetal bovine serum, 5% horse serum, glutamine
and penicillin/streptomycin cocktail. At log phase of growth (60-80% confluency), the
media was exchanged for 400 µL of serum-free media (OptiMEM, Invitrogen). For each
well, transfection was carried out with a total of 1 µg of plasmid DNA premixed and
preincubated with 3 µL of Lipofectamine LTX (Invitrogen) in 100 µL of OptiMEM. Twenty
four hours after transfection, HEK 293 cells were fixed in 4% paraformaldehyde for 10
minutes, fixed in 5% goat normal serum for one hour and either used immediately for
immunocytochemistry or frozen at -80oC for later use.
Electrophysiological assays
Whole cell current clamp and voltage clamp measurements were recorded from div
17-21 neurons that had been treated with patient or control CSF for the duration
specified. Extracellular solution was perfused at 1 ml/min and was composed of (in mM):
140 NaCl, 3 KCl, 2.5 CaCl2, 0.6 MgCl2, 30 glucose, 10 HEPES, pH titrated to 7.4 with
10N NaOH. Patch pipette electrodes were prepared from borosilicate glass with
resistance within 4-8 MΩ. The composition of intracellular solution was (in mM): 140
Kgluconate, 2 MgCl2, 10 HEPES, 11

EGTA, 7 glucose, 2 ATP, 0.3 GTP, pH
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7.3. The pharmacological agents used were racemic baclofen (1 mM in water, pH 7.4
with NaOH, Tocris) and CGP7930 (10 mM in DMSO, Tocris) at the indicated
concentrations. Before a gigaOhm seal was formed on neurons, voltage offset was
compensated. Membrane resistance, series resistance, and membrane capacitance
were determined from current transients elicited by a 5 mV depolarizing step from a
holding potential of -80 mV before switching to current clamp mode with a command
current of 0 mA. Membrane potential was amplified and low pass filtered with a 5 KHz
cutoff Bessel filter before being sampled and digitized at 10 KHz. Firing rate was
determined offline using StimFit (Schlögl et al., 2013). Action potential recordings were
acquired in current clamp mode. Action potentials were detected by counting threshold
crossing of the first time derivative of the membrane potential trace.
Statistical Analysis
Data that passed tests for normality by the D’Agostino and Pearson test were
analyzed with parametric tests, specifically t test for one factor with two levels, one-way
ANOVA for multi-level experiments and two-way ANOVA for two factor experiments.
Post-hoc testing for group differences in parametric tests was one using the Dunn test.
In experiments where the sample statistic had a theoretical maximum or a minimum and
deviated from normality were tested using non-parametric Kruskal-Wallis test with the
Holm-Sidak post-hoc test for group differences.
Analysis of antagonism by patient CSF was done using Gaddum/Schild EC50 shift
analysis by parametric nonlinear fitting in GraphPad Prism. The firing rate in the
presence of GABAB ligands was converted to efficacy in percent. Firing rate that was
identical to baseline was set as 0% efficacy while a firing rate of 0Hz i.e. maximal
inhibition in the presence of drug was set as 100% efficacy. pA2, B and Schild slope
were shared parameters between

CSF concentration or duration of CSF
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incubation but, the Hill slope parameter was unconstrained.
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Results
Patient CSF contains antibodies that bind to GABAB1 receptors
CSF samples from 10 patients with GABAB antibodies whose clinical characteristics
were described previously (Lancaster et al., 2010; Höftberger et al., 2013) were used in
these studies. We determined that all patients whose CSF was used in this study had
anti-GABAB immunoglobulins by immunostaining unfixed, unpermeabilized cultured rat
hippocampal neurons. Confocal microscopy confirmed that 10/10 patient CSF samples
labeled clusters on the surface of cell bodies and processes (N = 3 replicates, 2-3
coverslips each, 4 neurons/coverslip). Whether these clusters contained GABAB1
receptors was determined by analyzing images from neurons that were subsequently
fixed, permeabalized and labeled with a commercial antibody to an intracellular GABAB1
receptor epitope. Nearly all (85  7%; N = 1 replicate, 3-8 coverslips each, 4
neurons/coverslip) human IgG-bound surface clusters were also labeled with the
GABAB1 antibody (Fig. 1B) overlapped with a subset of clusters (41  15%) recognized
by a commercial antibody to an intracellular epitope on GABAB1 receptor (Fig. 1B). This
confirms that the immunoglobulins in patient CSF recognize the GABAB1 receptor
subunit (Lancaster et al., 2010).
To verify that patient CSF autoantibodies bind directly to GABAB1 receptors and not
to other proteins that colocalize with GABAB1, HEK293 cells were transfected with cDNA
constructs encoding GABAB1a and GABAB2 receptors and immunostained with patient
CSF and/or commercial GABAB1 receptor antibodies. Cells that expressed GABAB1
were identified after immunostaining with commercial GABAB1 antibodies (N = 2-10
replicates, 2-5 coverslips each). All cells that expressed GABAB1 also bound human IgG
from the CSF of the 10 patients used (Fig. 1C).
While CSF from patients

contains antibodies to GABAB1
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receptors, it is possible that some of the neuronal reactivity with CSF could be explained
by antibodies to other neuronal proteins. To evaluate this possibility, we immunostained
sagittal brain sections from Gabbr1-null mice and wild-type littermates with CSF from
patients and controls (Fig. 1D). All three patient CSFs tested, but not three control CSFs,
strongly stained hippocampus, thalamus and striatum in wild-type brain sections in a
pattern similar to their staining of wild-type rat brains (Lancaster et al., 2010). In contrast,
neither patient CSF nor control CSF stained Gabbr1-null brain sections (Fig. 1D). These
results suggest that the patient CSFs tested contain antibodies only to GABAB1 receptor
subunit.
Taken together, these results confirm that patients with anti-GABAB1 receptor
encephalitis have immunoglobulins in their CSF that bind to GABAB1 receptors and that
this binding accounts for the reactivity of their CSF with brain tissues.
Patient antibodies bind to GABAB1a receptor Sushi domains
Antibodies in patient CSF bind to an extracellular region of the GABAB1 receptor
subunit, as evidenced by surface staining of unfixed, unpermeabilized neurons (Fig. 1;
Lancaster et al., 2010). GABAB1 is comprised of a large N-terminal extracellular domain
(NTD) that is linked to the seven transmembrane domain typical for the GPCR
superfamily. The only extracellular epitopes of GABAB1 are the NTD and the linkers
between transmembrane helices 2-3, 4-5, and 6-7. To determine the minimal GABAB1
epitope required for patient antibody binding, cDNAs encoding GABAB1 receptors with
different deletions (Fig. 2A) were expressed in HEK cells, followed by immunostaining
with patient CSF.
When the NTD was deleted, 10/10 patient CSFs tested (N = 4 replicates, 6-10
coverslips, 100-200 cells) no longer bound to HEK293 cells expressing GABAB1 NTD
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(Fig. 2B). These results demonstrate that the NTD is necessary for autoantibody binding.
The NTD in GABAB1a has two subdomains, the ligand-binding Venus Flytrap
Domain (VFT) and the alternatively spliced doublet of Sushi domains (SD) at the aminoterminus (Fig. 2A). All (7/7) patient CSFs tested bound to HEK cells transfected with the
construct lacking the VFT domain (VFT) (Fig. 2C; N = 3 replicates, 3 coverslips, 100200 cells). This result shows that the VFT is not the immunodominant domain of
GABAB1.
Since the majority of the residues in the NTD make up the VFT, we next assessed
the smaller SDs and short inter-domain loops as potential immunodominant domains.
When SDs were deleted from GABAB1a, 3/3 patient CSFs tested no longer bound to
transfected HEK cells (Fig. 2D; N = 2 replicates, 1 coverslip, 100 cells). This result
indicates that the SDs is necessary for autoantibody binding.
It is possible that deleting GABAB1 domains interfered with the correct folding of the
remaining tertiary structure. Even if a misfolded protein remnant contained the epitope, it
might fail to bind antibodies. To further confirm that the immunodominant epitope is
within the SD, and the loss of autoantibody staining in the ∆SD construct was not due to
a misfolded or otherwise blocked epitope on the remaining protein, the SD was fused to
a membrane carrier derived from mouse CD8 receptors (NTD::CD8). HEK cells
transfected with the NTD::CD8 fusion construct bound human autoantibodies from 3/3
patient CSFs (Fig 2E; N = 2 replicates, 2 coverslips; 100 cells).
Taken together, these data show that the alternatively spliced SDs in GABAB1a are
necessary and sufficient for antibody binding.
Patient CSF antibodies do not reduce surface receptor cluster density
Previous work has shown that divalent antibodies in CSF from patients with anti67

NMDAR or anti-AMPAR encephalitis induces surface receptor loss, due to receptor
crosslinking and internalization into recycling endosomes and lysosomes (Lai et al.,
2009; Hughes et al., 2010; Moscato et. al., 2014; Peng et al., 2015). To determine
whether GABAB1 autoantibodies similarly crosslinked and internalized surface GABAB
receptors, cultured neurons were treated with patient CSF for 24 hours followed by
immunostaining and image analysis obtained by confocal microscopy.
As previously reported (Hughes et al., 2010; Moscato et al., 2014), a decrease in
surface NMDA receptor clusters was observed after 24 h treatment with patient
compared to control CSF (Fig. 3A-B, right patient CSF 9.6  1.4 clusters/20 m; control
CSF 5.5  1.4 clusters/20 m; significantly different, p < 0.05; N = 2 patient and 2 control
CSFs, 3 coverslips/patient, 4 neurons/coverslip). To assess antibody bound clusters
that were internalized, neurons were treated with patient CSF for 24 hours, fixed,
permeabilized and incubated with a secondary antibody to human IgG conjugated to
Alexa 594. A concomitant increase in internalized receptor clusters was observed after
24 h treatment with anti-NMDA receptor encephalitis patient compared to control CSF,
as previously reported (Hughes et al., 2010; Moscato et al., 2014) (Fig. 3C, right; antiNMDA receptor encephalitis patient CSF 4.0  0.2 clusters/20 m; control CSF 0.1  0.2
clusters/20 m; significantly different, p < 0.001). Surprisingly, no change in the density
of surface GABAB receptor clusters was observed after 24 h treatment with patient
compared to control CSF. Treatment with 5 patient and 5 control CSFs followed by
analyses of receptor cluster density as well as area and intensity were used to confirm
the lack of receptor internalization by patient GABAB1 antibodies (N = 3 experiments, 815 coverslips/CSF, 4 neurons/coverslip). Treatment of cultured hippocampal neurons
for 24 h with patient or control CSF resulted in no change in cluster density (patient CSF
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12.3  1.22 clusters/20 m; control CSF14.1 1.11 clusters/20 m; not significantly
different, p = 0.29), area (patient CSF 0.17  0.008 m2; control CSF 0.18  0.008 m2,
not significantly different, p = 0.50) or intensity (patient CSF 80.1  6.7; control CSF 78.1
 5.3 arbitrary values; not significant, p = 0.81) (Fig. 3D-F). Taken together, these data
indicate that total surface GABAB1 receptors are unchanged by patient antibodies after
24 h of treatment. No change in internalized receptor clusters was observed after 24 h
treatment with patient compared to control CSF (Fig. 3C, left; patient CSF 0.1  0.1
clusters/20 m; control CSF 0.1  0.1 clusters/20 m; not significantly different, p =
0.20).
To determine whether longer antibody exposure led to loss of surface GABAB1
receptor clusters and/or other structural changes, neurons were treated for 1, 2, 3 and 7
days with patient and control CSF followed by immunostaining with patient CSF to detect
surface GABAB receptors, a commercial antibody to an intracellular GABAB receptor
epitope to detect both intracellular and surface GABAB receptors, and Bassoon
antibodies to stain presynaptic terminals. No change in surface GABAB receptor clusters
was observed after 1 to 7 days of treatment (Fig. 3D; 1 day patient 16.2  4.0 clusters/20
m, control 15.6  4.0, p = 0.99; 2 days patient 13.7  4.9 clusters/20 m, control 13.9 
5.0, p = 0.99; 3 days patient 11.5  3.7 clusters/20 m, control 19.0  3.6, p = 0.17; 7
days patient 14.7  5.8 clusters/20 m, control 11.6  6.0, p = 0.97; not significantly
different, 2-way ANOVA, CSF treatment F(1,37) = 0.17, p = 0.67 followed by Holm-Sidak
multiple comparisons). In addition, no reduction was observed in GABAB1 receptor
clusters recognized by the commercial GABAB antibody (Fig. 3E; 2-way ANOVA, CSF
treatment F(1,37) = 1.46, p = 0.233). Treatment with patient or control CSF for 1 to 7
days did not result in a change in presynaptic terminal density visualized by staining for
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Bassoon (Fig. 3F; 2-way ANOVA, CSF treatment F(1,39) = 0.02, p = 0.88).
We used an alternate method to measure the quantity of surface GABAB receptors.
Surface biotinylation followed by Western blot analysis of GABAB1 showed no difference
between surface GABAB1 protein after either 24 h or 72 h treatment in patient or control
CSF (Fig. 3G). Similarly, no difference was observed in total GABAB receptor protein,
surface GABAA or GluR1 receptor protein after 24 or 72 h treatment with patient or
control CSF.
Taken together, these data show that, contrary to autoantibodies from anti-NMDA
receptor, anti-AMPA receptor or anti-GABAA receptor encephalitis patients, GABAB1
autoantibodies do not change surface GABAB receptor cluster density or protein level,
total receptor protein expression, internalized clusters, other synaptically localized
receptors (GABAA, GluR1 receptors) or presynaptic terminals.
Patient antibodies block GABAB receptor activation
We next investigated whether patient GABAB receptor antibodies have functional
effects on GABAB receptor mediated signaling. We used the inhibition of action potential
firing rate by a GABAB agonist as a functional readout of GABAB activation in cultured
hippocampal neurons. Cultured hippocampal neurons form networks in vitro
characterized by spontaneous action potential firing ranging from 0.5 to 5 Hz. Baclofen,
a GABAB receptor specific agonist (Bowery, 1993) that inhibits action potential firing
was used as a positive control. Treatment with 1-100 M baclofen for 0.5-5 min
eliminates action potential firing (Misgeld et al., 1995), likely due to inhibition of
presynaptic terminals via GABAB1a-containing receptors (Howe et al., 1987; Harrison,
1990; Scanziani et al., 1992).
Consistent with previous work, whole cell recording in current clamp mode with no
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current injection showed that cultured hippocampal neurons fired in the range of 1-10 Hz
(mean 3.53 ± 0.91 Hz, N = 15 coverslips, 2 neurons/coverslip). After treatment with 100
M baclofen, the action potential firing rate was dramatically reduced to at most 0.05 Hz
(Fig. 4A-B; mean 0.031 +/- 0.008 Hz, N = 20 coverslips, 1 neuron/coverslip). However,
cultured hippocampal neurons do not have a high baseline GABAB tone, because a high
concentration (1 M) of a potent GABAB antagonist CGP55845 (Kd = 30 nM; Brugger et
al., 1993) did not change the firing rate (data not shown). Consistent with this, baseline
firing rate is similar in neurons treated with either patient or control CSF (control CSF
3.54 ± 0.92 Hz, N = 2 CSFs, , 9 coverslips, 1 neuron/coverslip; patient CSF 2.85  0.41
Hz, N = 3 CSFs, 15 coverslips, 1 neuron/coverslip (Fig. 4B; not significantly different,
t(22) = 0.68, p = 0.45).
We analyzed the block of GABAB activation by 100 µM baclofen mediated by CSF
from several controls and patients. Baclofen (100 M) significantly reduced the firing rate
of neurons pretreated for 24 hours with control CSF but was less efficacious in inhibiting
the firing rate in neurons pretreated with anti-GABAB receptor encephalitis patient CSF
(Fig. 4B). The efficacy of baclofen can be operationally defined as the relative reduction
in the five minute average of firing rate during perfusion with baclofen relative to
perfusion with artificial CSF. A 100 µM of baclofen was nearly maximally efficacious in
inhibiting neurons treated with CSF from five different control patients similar to neurons
that were not pretreated with CSF (efficacy ranges from 94.2% to 99.5%, p>0.99 for
control CSF treated neurons compared to no treatment, N=5-8 coverslips, Dunn's
multiple comparison post Kruskal-Wallis; Fig 4C). In contrast, neurons pretreated with
CSF from patients 1, 2, and 3 were minimally silenced by 100 M baclofen: -1.8  5.4%
(N = 16 coverslips, p<0.001), 10.3  6.9% (N = 5 coverslips, p=0.005), and 26.6  7.7%
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(N = 10 coverslips, p = 0.001), respectively (mean percent of baseline  SEM, p-values
from Dunn's multiple comparison post Kruskal-Wallis non-parametric two factor analysis;
Fig. 4C). These data indicate the patient GABABR1 autoantibodies are antagonists of
GABAB receptors.
Patient GABABR1 antibodies do not inactivate GABAB2 mediated signaling
The above data show that patient CSF abrogates GABAB function in neurons in
vitro without reducing the number of surface GABAB receptors. We examined the
possibility that patient antibodies disrupt GABAB activation by rendering them nonfunctional or inactivated by using a GABAB2 agonist, CGP7930, which binds to the
heptahelical domain of GABAB2, directly activating it, which in turn activates G-protein
signaling even in the absence of any agonist binding to GABAB1 (Binet et al., 2004; Chen
et al., 2005).
Neurons were pretreated with the most potent patient CSF (patient 1), then treated
with 2, 10, or 100 µM baclofen, and then with 100 µM CGP7930. Compared to control
CSF treated neurons, 2, 10, or 100 uM baclofen was less efficacious in patient CSF
treated neurons by 99  21% (p < 0.001, N = 3 coverslips), 69  17% (p = 0.001, N = 5
coverslips) , and 55  17% (p = 0.006, N = 9 coverslips), respectively (1 neuron/coverslip
in each condition; Holm-Sidak multiple comparisons post two-way ANOVA). Despite the
antagonistic effect on baclofen efficacy by GABAB1 autoantibodies in patient CSF, the
GABAB2 agonist CGP7930 (100 µM) was equally efficacious in both control CSF or
patient CSF treated neurons (Fig. 5A and 5B; control CSF: 99.5  0.2%, patient CSF:
99.1  0.3%; N = 4 coverslips, p = 0.98). These results indicate that patient GABAB
autoantibodies prevent GABAB1 activation by agonists, but do not affect the ability of
GABAB2 or downstream second messenger molecules to respond to GABAB receptor
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mediated G protein activation.
Patient antibodies are competitive antagonists of GABAB receptors
To dissect the mechanism by which GABABR1 autoantibodies block GABAB
receptor functions, we decreased the duration of exposure to autoantibodies before
adding various doses of baclofen. In as little as 30 minutes of treatment with patient
CSF, the efficacy of 3 M baclofen was reduced to 34  18% but the efficacy of 10 M
(84  3%) or 100 M (99%) baclofen remained largely unchanged. This represents a
rightward shift in logEC50 of baclofen-mediated neuron silencing from -6.4  0.6 in the
absence of patient CSF to -5.3  0.02 after 30 minutes of treatment with patient CSF. By
2.5 hours, the block of GABAB activation by patient CSF is nearly maximal with a further
shift in logEC50 to -2.1  0.5 (Fig. 6A). Statistical analysis confirms that the interaction of
time x drug concentration has a significant effect on the baclofen block (F(8,96) = 6.2,
p<0.0001). These data suggest that the block of GABAB receptors by autoantibodies in
patient CSF is rapid compared to the 24 hours it takes for the surface density of NMDA
receptors to reach half-maximal level after cross-linking and internalization in anti-NMDA
receptor encephalitis (Moscato et al., 2014).
We evaluated the possibility that autoantibodies irreversibly bind to GABAB
receptors and render them non-functional using a patient CSF of lower titer and thus
potency (patient 4). The GABAB autoantibodies in patient 4 CSF inhibit baclofenmediated silencing in a dose dependent manner (Fig. 6B; CSF concentration x baclofen
concentration F(4,194) = 29.5, p<0.0001, N = 3 experiments 3 coverslips, 1
neuron/coverslip for each condition). After treatment with a 1:100 dilution of patient 4
CSF, the efficacy of 3 M, 10 M and 100 M of baclofen was nearly maximal (94  3%,
92  3% and 96  2%, respectively). This corresponds to a logEC50 of approximately -6.6
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 0.4. However, after treatment with a 1:20 or 1:5 dilution of patient 4 CSF, baclofen
efficacy was greatly reduced in a CSF concentration dependent manner (1:20 CSF,
logEC50 = -4.7  0.07 and 1:5 CSF, logEC50 = -3.9  0.1). Thus, increasing the
baclofen concentration can overcome GABAB receptor block by patient GABAB
autoantibodies, and an increasing titer of the patient CSF treatment result in a dextral
shift in the dose-response curve of baclofen efficacy (Fig. 6B). These data suggest that
patient GABABR autoantibodies may be competitive antagonists of GABAB receptors.
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Discussion
Our work confirms that autoantibodies from anti-GABAB receptor encephalitis
patients bind to GABAB1 receptors (Lancaster et al., 2010), and extends it several ways.
We show that the Sushi domain present in the presynaptically localized GABAB1a isoform
is necessary and sufficient to bind patient anti-GABAB receptor antibodies, suggesting
that the effects of GABAB receptor antibodies occur presynaptically. We demonstrate
that GABAB receptor autoantibodies do not change surface GABAB receptor localization,
in contrast to NMDA receptor autoantibodies from anti-NMDA receptor encephalitis
patients. GABAB receptor autoantibodies block GABAB receptor activation by baclofen,
suggesting that the clinical manifestations of GABAB receptor autoantibodies result from
diminished GABAB receptor function, a mechanism which, to our knowledge, has never
been observed in any other autoimmune disease. Patient GABAB receptor
autoantibodies do not inactivate GABAB receptors, however, because the patient
antibody mediated baclofen block was circumvented by directly activating the GABAB2
subunit with a selective partial allosteric agonist, CGP7930. We conclude that patient
GABAB1 receptor autoantibodies are selective allosteric antagonists of presynaptic
GABAB1a,2 receptors. This work raises the clinically important hypothesis: GABABR2
agonists may treat the intractable seizures that are the primary cause of morbidity and
mortality in patients with anti-GABAB receptor encephalitis.
The Sushi domain of GABAB1a is necessary and sufficient to bind autoantibodies
from all anti-GABAB encephalitis patients we tested. The immunodominant domain
recognized by anti-GABAB receptor antibodies is distinct from what has been identified in
anti-NMDAR or anti-AMPAR encephalitides. In all anti-GABAB encephalitis patients
tested here, autoantibodies bound to a 150 amino acid N-terminal portion of the receptor
consisting of two Sushi domains,

which are present in the
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presynaptically localized GABAB1a subunit of GABAB receptors but not the GABAB1b
subunit. Autoantibodies from patients with anti-NMDA receptor or anti-AMPA receptor
encephalitis bind to the auxiliary amino-terminal domain that is homologous to bacterial
periplasmic amino acid binding proteins (PBPs, Gleichman et al., 2012, 2014; O’Hara et
al., 1993).
Similar to ionotropic glutamate receptors, Class III GPCRs, of which GABAB
receptor is one, contain a domain homologous to bacterial periplasmic amino acid
binding proteins, the Venus Flytrap domain, that binds ligand (Acher and Bertrand,
2005). Our results show that the VFT domain of GABAB1 does not bind patient
autoantibodies. That the immunodominant domain in patients with anti-GABAB
encephalitis is structurally distinct from that recognized by antibodies from patients with
anti-NMDA or anti-AMPA receptor encephalitis may account for the strikingly different
effects of these patients’ antibodies on surface receptor localization.
In anti-NMDA, anti-AMPA and anti-GABAA receptor encephalitides, patient
autoantibodies decrease cognate receptors at synapses and in cell membranes,
whereas GABAB receptor autoantibodies did not change surface GABAB receptor
localization. The target antigens in the encephalitides associated with NMDA, AMPA or
GABAA receptors are generally present in two copies in an oligomeric configuration, e.g.,
two subunits of GluN1, GluA1, GluA2 or GABAAβ3 in heterooligomeric receptors. Thus
two autoantibody binding sites are present on each ionotropic receptor, perhaps
facilitating their clustering or aggregation by divalent autoantibodies. NMDA receptor
internalization caused by antibodies from anti-NMDA receptor encephalitis patients is
dependent on the divalency of patient IgGs (Hughes et al., 2010; Moscato et al., 2014).
In contrast, GABAB receptors are most often present in neurons as heterodimers;
autoantibodies thus bind to one

epitope for every assembled receptor
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on the cell surface. This difference may explain why treatment with GABAB1
autoantibodies does not result in GABAB receptor internalization.
Identification of the immunodominant domain may also shed light on the
pathophysiologic mechanism mediated by GABAB receptor autoantibodies. The GABAB1a
subunit containing GABAB(1a,2) heterodimeric receptor is preferentially trafficked to
pyramidal neuron axons (Vigot et al., 2006; Laviv et al., 2011; Degro et al., 2015). When
activated, this receptor inhibits glutamate release from glutamatergic terminals
(Biermann et al., 2010). Either of the two Sushi domains present in GABAB1a is sufficient
to traffic the subunit to the axonal domain (Vigot et al., 2006; Hannan et al., 2012).
While patient autoantibodies are functional GABAB receptor antagonists, it is possible
that autoantibodies also affect receptor trafficking and presynaptic localization by
blocking the two Sushi domains.
Taken together, autoantibody binding to Sushi domains, failure of autoantibodies to
decrease surface GABAB receptors and autoantibody-mediated block of baclofenmediated inhibition of neuronal excitability is consistent with GABAB1 autoantibodies
being allosteric antagonists of GABAB receptors. It is possible that antibody bound
GABAB receptors are inactivated and cannot signal through G proteins. This seems
unlikely, because even in saturating doses of baclofen, GABAB2 could be activated by a
partial allosteric agonist in cells treated with patient autoantibodies. Our data can’t
exclude the possibility that patient autoantibodies disrupt heterodimerization of ligand
binding GABAB1 and the G-protein activating GABAB2 subunits. However, this possibility
seems unlikely because receptors remain activatable by saturating doses of baclofen, a
GABAB1 agonist. The regions of GABAB1and GABAB2 that are necessary for
dimerization are the C-terminal coiled-coil domain and the upper lobe of the VFTs.
Moreover, interaction between the

VFTs of GABAB1 and GABAB2 increase
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the affinity of GABAB1 for agonists and antagonists 10-100 fold (Pin et al., 2004). It is
possible that the steric bulk of an IgG bound to the Sushi domains in GABAB1a subunit
affects the interaction of the GABAB1 and GABAB2 VFTs, reducing the affinity of GABAB
receptors to baclofen. This is supported by our observation that the block of baclofenmediated inhibition of neuronal excitability by patient autoantibodies is surmountable by
increasing the baclofen concentration. Together, our data suggest that patient GABAB
autoantibodies are surmountable allosteric antagonists of GABAB receptors.
In anti-GABAB receptor encephalitis patients, autoantibodies may contribute to
seizures by interfering with GABA-mediated inhibition of neuronal firing. Development of
CNS penetrant GABAB2 heptahelical domain agonists that rescue autoantibody
antagonism in vitro may provide a viable therapeutic intervention to control the
intractable seizures that are often the cause of death in anti-GABAB receptor
encephalitis patients.
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Figures
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Figure 1. Cerebrospinal fluid (CSF) from patients contains antibodies that bind to
GABAB1 receptors.
(A) Immunostaining of mouse saggital brain sections with patient CSF shows binding in
hippocampus, thalamus, striatum and cerebellum (brown); sections counterstained with
hematoxylin (purple). Scale bar = 1mm.
(B) Immunostaining of unfixed and unpermeabilized 14 div hippocampal neurons with
patient CSF (green), followed by permeabalization and staining with commercial
antibodies to an intracellular GABAB1 epitope (red). Boxed area in neuron on left shown
at higher magnification to right (scale bars = 5 um).
(C) Immunostaining of fixed, permeabalized HEK293T cells expressing GABAB1a and
GABAB2 with patient CSF (green) and commercial GABAB1 antibody (red). Scale bar =
20 um.
(D) Immunohistochemical staining of mid saggital brain sections from GABAB1 knockout
mice (left) or wild type littermates (right) with patient CSF. In wildtype mice, patient CSF
prominently stains hiccpocampus (hc), thalamus (th) and the striatum (str), while in
knockout mice, patient CSF does not stain any brain structure above background. Scale
bar = 500um.
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Figure 2. Sushi domains in GABAB1a are the dominant epitope for autoantibodies in
patient CSF.
(A) left: Diagram of the tertiary structure of GABAB receptor comprised of GABAB1 and
GABAB2. right: Domain structure of GABAB1 comprised of Sushi domains (blue), ligand
binding Venus Flytrap domain (pink) and seven transmembrane domain (black). The
myc epitope in the transfected construct and the epitope recognized by a commercial
GABAB1 antibody are represented by a red and a blue asterisk, respectively.
(B-E) HEK293T cells expressing wildtype (A) or deletion (B-D) GABAB1a and GABAB2
immunostained with patient CSF (green, left column), N-terminal myc antibody (red,
middle left column) or C-terminal intracellular GABAB1 antibody (blue, middle right
column). Cells expressing each deletion construct were immunostained for the Nterminal myc and C-terminal GABAB1 epitope. (B) Immunostaining is present in cells
expressing full length GABAB1. (C) Immunostaining is absent in cells expressing NTD
deleted GABAB1. C: Immunostaining is present in cells expressing VFT deleted
GABAB1, although staining appears qualitatively reduced compared to cells expressing
full length receptors. (D) Immunostaining is absent in cells expressing GABAB1 lacking
both Sushi domains. (E) HEK293T cells expressing fusion proteins of GABAB1a and a
mouse CD8 receptor fragment.
(F) The GABAB1a N-terminal domain alone is sufficient to bind patient GABAB1
antibodies (left). The VFT alone does not bind patient GABAB1 antibodies (middle;
image was gamma shifted so background staining is apparent). The Sushi domains
(SD) alone are sufficient to bind to human autoantibodies (right). These data
demonstrate that the Sushi domains are necessary and sufficient to bind patient
GABAB1 antibodies. Scale bars = 20 um.
82

83

Figure 3. Patient GABAB1 antibodies from patients with anti-GABAB receptor
encephalitis do not reduce surface receptor clusters.
(A) Unfixed, unpermeabalized hippocampal neurons treated with patient or control CSF
for 24 hours followed by immunostaining with patient CSF and anti-human Alexa 488
conjugated secondary antibody (green). Internalized patient IgG was visualized after
fixation, permeabilization and immunostaining with anti-human Alexa 594 conjugated
secondary antibody (red). Left: After 24 h treatment, the density of surface clusters is
the same in patient and control CSF treated neurons, and no internalized clusters are
detected (N = 3 patient CSF, 4-6 coverslips/patient, 4 cells/coverslip). Right: In
contrast, after 24 h treatment with CSF from anti-NMDAR encephalitis patients, a
significant reduction in surface clusters and a significant increase in internalized clusters
are detected, as previously reported (Hughes et al., 2010; Moscato et al., 2014; N = 2
patient CSF, 4-6 coverslips/patient, 4-5 cells/coverslip). Scale bar = 5 um.
(B) Quantification of immunostaining shows that after 24 h treatment, the density of
surface GABAB1 clusters are not significantly different in patient or control CSF treated
neurons (Student’s t test, p = 0.85), while 24 h treatment with CSF from anti-NMDA
receptor encephalitis results in a significant reduction in surface clusters compared to
control CSF treated neurons (Student’s t test p < 0.05).
(C) Quantification of immunostaining shows that after 24 h treatment, few if any
internalized GABAB1 clusters are detected in patient or control CSF (Student’s t test, p =
0.21), while the density of internalized clusters is significantly higher in cells treated with
CSF from anti-NMDA receptor encephalitis patients compared to controls (Student’s t
test, p < 0.05).
(D-F) Duration of patient CSF treatment for up to 7 days does not affect surface
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GABAB1 receptor cluster or presynaptic terminal density. Quantification of surface
GABAB1 (D), total GABAB1 (E) and presynaptic Bassoon (F) cluster density in neurons
treated for 1, 2, 3 and 7 days with anti-GABAB1 patient or control CSF (N = 5 patient
CSF and control samples, 8-15 coverslips/patient, 4 neurons/coverslip).
(H) Surface biotinylation and Western blot of surface and total protein fractions isolated
from patient or control CSF treated neurons. Surface GABAB 1 receptor protein level is
not different in patient or control treated neurons after 24 or 72 hrs (N = 1 patient
sample, same samples used for 24 and 72 h treatment; 5 coverslips/patient). GABAA
protein band controls for quantity of protein in surface fraction of protein lysates. No
change in surface AMPA receptor protein (GluR1) or total GluR1 was observed. MAP2
protein band controls for the quantity of protein in the total lysate. (Right) There is no
difference in total GABAB1 protein levels in patient or control treated neurons after 24 or
72 hrs (N = 1 patient sample, same samples used for 24 and 72 h treatment; 5
coverslips/patient).
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Figure 4. Patient GABAB1 antibodies block GABAB receptor activation.
(A) Whole cell current clamp traces before, in presence of 100 um baclofen (solid bar)
and after washout. Top: Cells treated with control CSF show block of action potential
firing by baclofen. Bottom: Cells treated with patient CSF for 24 hours show no block of
action potential firing by baclofen. Scale bar = 60 s, 25 mV.
(B) Quantification of firing rate in one minute bins, normalized to the mean firing rate
between t=-3 min to t=0 min. Solid bar indicates infusion of 100 uM baclofen for 10
mins, beginning at t=0 min. Data between t = 5-10 min was excluded to illustrate
baclofen wash-on and off. After the onset of baclofen infusion, neurons stop firing action
potentials within 1-2 min in control CSF treated neurons (open circles). Firing rate is not
altered in patient CSF treated neurons (closed circles). Repeated measures ANOVA;
treatment X time F (13, 65) = 11.82 ; p < 0.05.
(C) Efficacy of 100 uM baclofen in neurons treated for 24 hours with 1:100 of CSF from
patients or controls. Efficacy is defined as the relative reduction in the five minute
average of firing rate of neurons during perfusion with baclofen relative to perfusion with
artificial CSF. Numerically, it is [1 – (average firing rate in region b/ average firing rate in
region a)] where regions a and b are labelled in Fig 4A. In 100 uM baclofen, baclofen is
maximally efficacious in control CSF treated neurons (gray circles, N = 6 control CSF, 520 coverslips/sample, 1 neuron/coverslip). Efficacy of 100 uM baclofen is reduced after
treatment with patient CSF (N = 3 patient CSF, 5-15 coverslips/sample, 1
neuron/coverslip; significantly different from control CSF, Dunn's multiple comparison
post Kruskal-Wallis non-parametric two factor analysis of variation, p = 0.001).
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Figure 5. Patient GABABR1 antibodies do not inactivate GABAB2 mediated signaling
(A) Whole cell current clamp trace during perfusion with the indicated concentrations of
either the GABAB1 binding agonist, baclofen or the GABAB2 binding agonist, CGP 7930
from a cultured hippocampal neuron treated for 24 hours with 1:100 of CSF from patient
1. Scale bar = 60 s, 25 mV.
(B) Efficacy of baclofen or CGP7930 at inhibiting firing in cultured neurons treated with
1:100 of CSF from patient 1. Despite being able to reduce the efficacy of baclofen even
at a concentration of baclofen at 100uM, treatment with patient CSF (black circles) is
unable to reduce the ability of CGP9730 at 100uM to silence neurons identically whether
they are treated with patient or control CSF (p = 0.40; Holm-Sidak multiplicity correction)
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Figure 6. GABAB1 autoantibodies are allosteric antagonists of GABAB receptors.
(A) Time course of onset of GABAB1 autoantibody mediated block of GABAB1
activation. Neurons were recorded after indicated duration of treatment with CSF from
case 1 in the presence of 3uM (light gray circles), 10uM (dark gray circles) or 100uM
(black circles) of baclofen. With increasing duration of exposure to GABAB1
autoantibodies, neurons required increasingly higher doses of baclofen to circumvent the
block on GABAB1 activation by antibodies. By 2.5 hours or treatment, even 100 uM of
baclofen was insufficient to overcome the antibody block of GABAB activation (ANOVA
Treatment duration X baclofen concentration F(8, 96) = 6.271; p<0.05) .
(B) Dose response of increasing concentration of GABAB1 autoantibodies. A lower titer
CSF (case 4) was used, which when used for treating neurons at 1:100 does not block
GABAB activation by baclofen. But after treatment with higher concentrations of CSF,
neurons are inhibited by baclofen only at 100uM (ANOVA, CSF concentration X baclofen
concentration F(4, 194) = 29.49; p<0.05)
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CHAPTER 3. Passive transfer model of anti-NMDA receptor
encephalitis
Adapted from: Jesús Planagumà et al. Brain 2015;138:94-109
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Abstract
Anti-N-methyl D-aspartate receptor (NMDAR) encephalitis is a severe
neuropsychiatric disorder that associates with prominent memory and behavioral
deficits. Patients’ antibodies react with the N-terminal domain of the GluN1 (previously
known as NR1) subunit of NMDAR causing in cultured neurons a selective and
reversible internalization of cell-surface receptors. These effects and the frequent
response to immunotherapy have suggested an antibody-mediated pathogenesis, but to
date there is no animal model showing that patients’ antibodies cause memory and
behavioral deficits. To develop such a model, C57BL6/J mice underwent placement of
ventricular catheters connected to osmotic pumps that delivered a continuous infusion of
patients’ or control cerebrospinal fluid (flow rate 0.25 µl/h, 14 days). During and after the
infusion period standardized tests were applied, including tasks to assess memory
(novel object recognition in open field and V-maze paradigms), anhedonic behaviors
(sucrose preference test), depressive-like behaviors (tail suspension, forced swimming
tests), anxiety (black and white, elevated plus maze tests), aggressiveness (residentintruder test), and locomotor activity (horizontal and vertical). Animals sacrificed at Days
5, 13, 18, 26 and 46 were examined for brain-bound antibodies and the antibody effects
on total and synaptic NMDAR clusters and protein concentration using confocal
microscopy and immunoblot analysis. These experiments showed that animals infused
with patients’ cerebrospinal fluid, but not control cerebrospinal fluid, developed
progressive memory deficits, and anhedonic and depressive-like behaviors, without
affecting other behavioral or locomotor tasks. Memory deficits gradually worsened until
Day 18 (4 days after the infusion stopped) and all symptoms resolved over the next
week. Accompanying brain tissue studies showed progressive increase of brain-bound
human antibodies, predominantly in the hippocampus (maximal on Days 13–18), that
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after acid extraction and characterization with GluN1-expressing human embryonic
kidney cells were confirmed to be against the NMDAR. Confocal microscopy and
immunoblot analysis of the hippocampus showed progressive decrease of the density of
total and synaptic NMDAR clusters and total NMDAR protein concentration (maximal on
Day 18), without affecting the post-synaptic density protein 95 (PSD95) and α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. These effects occurred in
parallel with memory and other behavioral deficits and gradually improved after Day 18,
with reversibility of symptoms accompanied by a decrease of brain-bound antibodies
and restoration of NMDAR levels. Overall, these findings establish a link between
memory and behavioral deficits and antibody-mediated reduction of NMDAR, provide the
biological basis by which removal of antibodies and antibody-producing cells improve
neurological function, and offer a model for testing experimental therapies in this and
similar disorders.

Introduction
Memory, learning, and behaviour depend on the proper function of the excitatory
glutamate N-methyl D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor (AMPAR) and underlying mechanisms of synaptic
plasticity (Lau and Zukin, 2007; Shepherd and Huganir, 2007). The critical role of
NMDAR in these functions has been shown in animal models in which the NMDAR are
altered genetically (Mohn et al., 1999; Belforte et al., 2010) or pharmacologically
(Jentsch and Roth, 1999; Mouri et al., 2007). In humans this evidence comes from more
indirect observations such as studies investigating the effects of phencyclidine or
ketamine (non-competitive antagonists of NMDAR that cause psychosis) (Weiner et al.,
2000; Gunduz-Bruce, 2009), and brain tissue studies of patients with schizophrenia or
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Alzheimer’s disease in which several molecular pathways that modulate glutamate
receptor trafficking or function are affected (Snyder et al., 2005; Hahn et al., 2006). In
2007 we identified a novel disorder (anti-NMDAR encephalitis) that occurs with highly
specific antibodies against extracellular epitopes located at the amino terminal domain of
the GluN1 subunit of NMDAR (Dalmau et al., 2007; Gleichman et al., 2012). The
resulting syndrome resembles the spectrum of symptoms that occurs in genetic or
pharmacologic models of NMDAR hypofunction, including memory loss and
neuropsychiatric alterations ranging from psychosis to coma (Dalmau et al., 2008; Irani
et al., 2010; Viaccoz et al., 2014). Regardless of the type of presentation, most patients
develop severe problems forming new memories and amnesia of the disease.
Symptoms are usually accompanied by systemic and intrathecal synthesis of antibodies,
the latter likely produced by plasma cells contained in brain inflammatory infiltrates
(Dalmau et al., 2008; Martinez-Hernandez et al., 2011). These long-lived plasma cells
and persistent antibody synthesis may explain the lengthy symptoms of most patients
(average hospitalization 3 months) (Dalmau et al., 2008). Yet, despite the severity and
duration of the disease, 80% of the patients have substantial recovery after
immunotherapy (accompanied by removal of an underlying tumor, usually an ovarian
teratoma, when appropriate), or sometimes spontaneously (Iizuka et al., 2008; Titulaer
et al., 2013).
Investigations on the potential pathogenic role of patients’ antibodies using cultured
neurons showed that the antibodies caused crosslinking and selective internalization of
NMDARs that correlated with the antibody titers, and these effects were reversible after
removing the antibodies (Hughes et al., 2010; Mikasova et al., 2012). In contrast,
patients’ antibodies did not alter the localization or expression of other synaptic proteins,
number of synapses, dendritic

spines, dendritic complexity, or cell
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survival (Hughes et al., 2010). In parallel experiments, the density of NMDAR was also
significantly reduced in the hippocampus of rats infused with patients’ antibodies, a
finding comparable to that observed in the hippocampus of autopsied patients (Hughes
et al., 2010). Overall, these studies suggested an antibody-mediated pathogenesis, but
the demonstration that patients’ antibodies caused symptoms remained pending.
Modelling symptoms and showing that these correlate with antibody-mediated reduction
of NMDAR would prove the pathogenicity of patients’ antibodies, support the use of
treatments directed toward decreasing the levels of antibodies or antibody-producing
cells, and help to investigate experimental therapies in this and similar disorders. We
report here such a model using continuous 14-day cerebroventricular infusion of
patients’ CSF in mice. The aims were to determine (i) if patients’ antibodies altered
memory and behaviour; (ii) whether mice symptoms correlated with brain antibodybinding and reduction of NMDAR; and (iii) whether the clinical and molecular alterations
recovered after stopping the antibody infusion.

Materials and methods
Animals
Male C57BL6/J mice (Charles River), 8–10 weeks old (25–30 g) were housed in
cages of five until 1 week before surgery when they were housed individually. The room
was maintained at a controlled temperature (21 ± 1°C) and humidity (55 ± 10%) with
illumination at 12-h cycles; food and water were available ad libitum. All experiments
were performed during the light phase, and animals were habituated to the experimental
room for 1 week before starting the tests. All procedures were conducted in accordance
with standard ethical guidelines (European Communities Directive 86/609/EU) and
approved by the local ethical committees: Comitè Ètic d’Experimentació Animal, Institut
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Municipal d’Assistència Sanitària (Universitat Pompeu Fabra), and Institutional Animal
Care and Use Committee (University of Pennsylvania).
Patients’ CSF samples
CSF from 25 patients with high titre NMDAR antibodies (all >1:320) were pooled
and used for cerebroventricular infusion. CSF from 25 subjects without NMDAR
antibodies (11 with normal pressure hydrocephalus and 14 with non-inflammatory CNS
disorders) were similarly pooled and used as controls. Before loading the osmotic pumps
(discussed below), the pooled CSF samples from patients and controls were dialyzed
(Slide-A-Lyzer 7K, Thermo) against sterile phosphate-buffered saline (PBS) overnight at
4°C, and the concentration of total IgG normalized to the CSF physiologic concentration
of 2 mg/dl. All mice received the same pooled CSF either from patients or controls.
Studies were approved by the institutional review board of Hospital Clínic and Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona.
Surgery, placement of ventricular catheters and osmotic pumps
Cerebroventricular infusion of CSF was performed using osmotic pumps (model
1002, Alzet) with the following characteristics: volume 100 µl, flow rate 0.25 µl/h, and
duration 14 days. Twenty-four hours before surgery, two osmotic pumps per animal were
each loaded with 100 µl of patient or control CSF. The pumps were then connected to a
0.28 mm IM (internal diameter) polyethylene tube (C314CT, PlasticsOne) and left
overnight in sterile PBS at 37°C. The next day, mice were deeply anaesthetized by
intraperitoneal injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg)
along with subcutaneous administration of the analgesic meloxicam (1 mg/kg). Mice
were then placed in a stereotaxic frame, and a bilateral catheter (PlasticsOne, model
3280PD-2.0/SP) was inserted into the ventricles (0.02 mm anterior and 1.00 mm lateral
from bregma, depth 0.22 mm) and

secured with dental cement. Each arm
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of the catheter was connected to one osmotic pump, which was subcutaneously
implanted on the back of the mice. Appropriate ventricular placement of the catheters
was assessed in randomly selected mice injecting methylene blue through the catheters
(Fig. 1A–C).

Cognitive tasks
All behavioral tasks were performed by researchers blinded to experimental
conditions using standardized tests reported by us (Maldonado et al., 1970; Filliol et al.,
2000; Berrendero et al., 2005; Bura et al., 2007, 2010, 2013; Aso et al., 2008;
Puighermanal et al., 2009; Burokas et al., 2012; Llorente-Berzal et al., 2013) and others
(Porsolt et al., 1977; Crawley and Goodwin, 1980; Handley and Mithani, 1984; Steru et
al., 1985; Konig et al., 1996; Caille et al., 1999; Strekalova et al., 2006; Taglialatela et
al., 2009; Ennaceur, 2010) and following the schedule summarized in Fig. 1D. The tasks
were aimed to assess memory (novel object recognition in open field and V-maze),
anhedonic behaviours (sucrose preference test), depressive-like behaviours (tail
suspension, and forced swimming tests), anxiety (black and white and elevated plus
maze tests), aggressiveness (resident-intruder test) and locomotor activity (horizontal
and vertical activity assessment). A brief description of each task is provided in the
Supplementary material.

Brain tissue processing
To determine the effects of patients’ antibodies on mouse brain, animals were
sacrificed at the indicated time points (Fig. 1D, Days 5, 13, 18, 26 and 46) with CO2.
Brains were harvested, sagittally split, and transferred to ice-cold PBS. Half of the brain
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was fixed by immersion in 4% paraformaldehyde (PFA) for 1 h at 4°C, cryoprotected with
40% sucrose for 48 h at 4°C, embedded with freezing media, and snap-frozen with
isopentane chilled with liquid nitrogen. The other half-brain was used for dissection of
hippocampus and cerebellum for IgG and protein extraction (see below).
Immunohistochemistry and quantitative peroxidase staining
For determination of antibodies bound to brain tissue using immunoperoxidase
staining, 7-µm thick tissue sections were sequentially incubated with 0.25% H2O2 for 10
min at 4°C, 5% goat serum for 15 min at room temperature, biotinylated goat anti-human
IgG (1:2000, Vector labs) overnight at 4°C, and the reactivity developed using avidinbiotin-peroxidase and diaminobenzidine. Sections were mildly counterstained with
haematoxylin, and results photographed under a Leica DMD108 microscope. Images
were prepared creating a mask for diaminobenzidine color, converting the mask to
greyscale intensities, and inverting the pixels using Adobe Photoshop CS6 package.
Hippocampal, frontal cortex, striatum and cerebellar regions were manually outlined;
intensity and area were quantified in two serial sections using the public domain Fiji
ImageJ software (http://fiji.sc/Fiji). Values were divided by area and normalized to the
group with the highest mean (defined as 100%, patients’ CSF treated animals sacrificed
at Day 18).
Immunofluorescence and confocal microscopy with brain tissue
For determination of antibodies bound to brain tissue using immunofluorescence, 5
µm-thick tissue sections were blocked with 5% goat serum and 1% bovine serum
albumin for 60 min at room temperature, and incubated overnight at 4°C with Alexa
Fluor® 488 goat anti-human IgG (A11013, diluted 1:1000, Molecular Probes/ Life
Technologies). Slides were then mounted with ProLong® Gold (P36930, Molecular
Probes) and results scanned under a

LSM710 Zeiss confocal microscope.
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Sections from all animals were analyzed in parallel. Quantification of fluorescent
intensity in areas of CA1, CA3 and dentate gyrus was done using Fiji ImageJ software.
Background was subtracted and intensity divided by area. Mean intensity of IgG
immunostaining in animals treated with patients’ CSF and sacrificed at Day 18 was
defined as 100%.
To determine the effects of patients’ antibodies on total and synaptic NMDAR
clusters and PSD95, non-permeabilized 5-µm thick sections were blocked with 5% goat
serum and 1% bovine serum albumin as above, incubated with human CSF antibodies
for 2 h at room temperature, washed with PBS, permeabilized with Triton™ X-100 0.3%
for 10 min at room temperature, and incubated with rabbit polyclonal antibody against
PSD95 (diluted 1:250, Clone 18258 Abcam) overnight at 4°C. Next day, the slides were
washed and incubated with the corresponding secondary antibodies, Alexa Fluor® 594
goat anti-human IgG and Alexa Fluor® 488 goat anti-rabbit IgG (A-11014, A-11008, both
diluted 1:1000, Molecular Probes) for 1 h at room temperature. Slides were mounted as
above and results scanned with a confocal microscope (Zeiss LSM710) with EC-Plan
NEOFLUAR CS ×100/1.3 NA oil objective. Standardized z-stacks including 50 optical
images were acquired from five different, equally spaced areas of CA1, CA3 and dentate
gyrus of hippocampus using sequential scanning, 1024 × 1024 lateral resolution, and
Nyquist optimized z-sampling frequency. Images were deconvolved with 20 iterations
using theoretical point spread functions and maximum likelihood estimation algorithms of
Huygens Essential software (Scientific Volume Imaging). For cluster density analysis a
spot detection algorithm from Imaris suite 7.6.4 (Bitplane) was used based on automatic
segmentation of the images to spots (Banovic et al., 2010). Density of clusters was
expressed as spots/µm3. Three-dimensional colocalization of clusters (e.g. NMDAR and
PSD95) was done using a spot co-

localization algorithm implemented in
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Imaris suite 7.6.4. Synaptic localization was defined as co-localization of NMDAR or
AMPAR with post-synaptic PSD95. Synaptic cluster density was expressed as
colocalized spots/µm3. For each animal, five identical image stacks in each hippocampal
area (CA1, CA2 and dentate gyrus) were acquired and the mean densities calculated for
total and synaptic NMDAR and AMPAR. Densities were normalized to the mean density
of control CSF treated animals (100%). For the AMPAR the antibody used was guinea
pig GluA1 antibody (1:100, clone AGP-009, Alomone), and as secondary antibody Alexa
Fluor® 594 goat anti-guinea pig IgG (A11076, 1:1000, Molecular Probes).
The presence of apoptosis, cellular infiltrates, and complement was assessed in
the hippocampal region (CA3) in mice sacrificed on Day 18 and corresponding controls.
Apoptosis was determined by standard terminal deoxynucleotidyl transferase mediated
biotinylated UTP nick end labelling (TUNEL) using the TACS 2TdT-Fluor in situ
apoptosis detection kit (Trevigen), and immunolabelling of cleaved caspase 3 (1:200,
#9661 Cell Signalling, Technologies) using a goat anti-rabbit Alexa Fluor® 488 as
secondary antibody (1:1000 Molecular Probes). The presence of complement was
assessed using rabbit anti-mouse C5b-9 (1:500, Abcam) and Alexa Fluor® 488 goat
anti-rabbit IgG (1:500, #A11008, Molecular Probes). Immunolabelling for T and B
lymphocytes was done using rabbit anti-mouse CD3 (1:1000, #ab16669 Abcam)
followed by secondary antibody goat anti-rabbit Alexa Fluor® 488 (1:1000, Molecular
Probes), and rat anti-CD45R (1/10000, #ab64100) followed by goat anti-rat Alexa Fluor®
594 (1/1000, #A-11007 Molecular Probes). Results were scanned with a confocal
microscope Zeiss LSM710.
Extraction of human IgG bound to mice brain
Under a dissection microscope (Zeiss stereomicroscope, Stemi 2000), the
hippocampus and cerebellum were

isolated, weighed, snap-frozen, and
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stored at −80°C. Tissue (10 mg) was homogenized in 0.5 ml ice-cold PBS with protease
inhibitors (Sigma-Aldrich) and centrifuged at 16 000g for 5 min. All steps were performed
at 4°C. Washing was repeated four times to remove unbound IgG. The last wash was
done in 100 µl and the supernatant saved as pre-extraction fraction. To extract the
specifically bound antibodies, the pellet was solubilized for 5 min in acid (86 µl 0.1 M Nacitrate buffer pH 2.7), centrifuged at 16 000g for 5 min, and the supernatant neutralized
with 14 µl 1.5 M Tris pH 8.8, and used to determine the presence of NMDAR (GluN1)
antibodies (see below).
Immunofluorescence with HEK293 cells expressing GluN1
The presence of GluN1 antibodies in IgG extracts from brain was determined using
a HEK293 cell-based assay expressing GluN1, as reported (Dalmau et al., 2008). After
fixation with 4% paraformaldehyde and permeabilization with 0.3% Triton™ X-100, cells
were blocked with 1% bovine serum albumin for 90 min, and incubated with undiluted
acid-extracted IgG or pre-extraction fraction from brain of infused mice, at 4°C overnight.
The next day, cells were washed and incubated with a mouse monoclonal antibody
against a non-competing GluN1 epitope located at amino acid 660-811 (1:20 000; clone
MAB363, Millipore) for 1 h at room temperature, followed by the corresponding Alexa
Fluor® secondary antibodies (A11013, A11032, both diluted 1:1000, Molecular Probes)
for 1 h at room temperature. The titre of positive samples was calculated by serial
dilutions until the reactivity was no longer visible. Results were photographed under a
fluorescence microscope using Zeiss Axiovision software.
Immunoblot analyses
Total protein from hippocampus and cerebellum was obtained by dissecting these
regions from 20-µm thick paraformaldehyde-fixed sagittal mouse brain sections on glass
slides at 4°C under a Zeiss

stereomicroscope (Stemi 2000). Two
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consecutive sections of isolated hippocampus or cerebellum were then transferred to an
Eppendorf tube in PBS supplemented with protease inhibitors. Loading buffer (RotiLoad)
was added, the solubilized tissue boiled for 5 min, and the proteins separated in a 10%
SDS gel electrophoresis with semi-dry blotting on PVDF membranes. Membranes were
blocked in 5% non-fat skimmed milk and incubated overnight at 4°C with the following
polyclonal rabbit antibodies: GluN1 (1:1000, Sigma-Aldrich), GluR2/3 (1:1000, Abcam),
and PSD95 (1:1000, Synaptic Systems), or a monoclonal mouse anti-β-actin (1:20 000,
Sigma-Aldrich). Membranes were incubated with secondary antibodies for 1 h at room
temperature (anti-rabbit IgG HRP 1:1000, anti-mouse IgG HRP 1:10 000) and analysed
by enhanced chemiluminescence (all Amersham GE Healthcare) on a LAS4000 (GE
Healthcare). All studies were done in duplicate. Analysed films were in the linear range
of exposure, digitally scanned, and signals quantified using Fiji ImageJ software. The
signal intensity of each antigen was normalized to that of actin in the same lane. The
mean intensity of signal in control CSF treated animals was defined as 100% and all
other intensities expressed in per cent relative to this value.
Statistics
Behavioural tests were analysed using repeated measures two-way ANOVA for
tests with multiple time points (novel object recognition, sucrose preference test,
resident-intruder test, locomotor activity), independent sample t-tests for tests with single
time points (forced swimming test, black and white test, elevated plus maze test) or by
Mann Whitney-U for skewed distributions (tail suspension test). Non-normally distributed
parameters were log-transformed (black and white test, elevated plus maze test).
Significance of NMDAR antibody titre in acid-extracted IgG fractions was calculated
using the Kruskal-Wallis test and Dunn’s post hoc test compared to titres at Day 46.
Human IgG intensity, confocal cluster

density and immunoblot data (GluN1,
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PSD95) from different time points or regions were analysed using two-way ANOVA with
Sidak-Holm post hoc testing to calculate multiplicity-adjusted P-values. Confocal cluster
density in the different hippocampal subregions (CA1, CA3, dentate gyrus) were not
significantly different and were analysed pooled. All experiments were assessed visually
for outliers (e.g. one animal with very different results from the other animals at the same
time point), but none were identified, so measurements were pooled per time point and
treatment (patient or control CSF). For confocal AMPAR cluster density measured at
single time points, independent sample t-tests were used. A P-value of <0.05 was
considered significant in post hoc testing after correction for multiple testing (SidakHolm). In the two-way ANOVA the cut-off for interaction between two factors was set at
0.10; if the P-value for interaction was <0.10, the effects of treatment were considered
for the separate time points (post hoc analysis). All tests were done using GraphPad
Prism (Version 6).

Results
One-hundred and eleven mice were included in the studies, 56 for cognitive and
behavioural tests, and 55 for assessment of antibody binding to brain and the effects on
total and synaptic NMDAR (Fig. 1).
Cerebroventricular infusion of patients’ CSF alters memory and behaviour in mice
The most robust effect during the 14-day infusion of patients’ CSF was on the novel
object recognition test in both the open field and V-maze paradigms (Fig. 2A and B).
Compared with animals infused with control CSF, those infused with patients’ CSF
showed a progressive decrease of the object recognition index, indicative of a memory
deficit (Bura et al., 2007; Puighermanal et al., 2009; Taglialatela et al., 2009). The
memory deficit became significant on Day 10 and was maximal on Day 18 (4 days after
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the infusion of CSF had stopped). On Day 25, the object recognition index had
normalized and was similar to that of animals treated with control CSF (Fig. 2A and B).
For all time-points, the total time spent exploring both objects (internal control) was
similar in animals infused with control or patients’ CSF (Supplementary Table 1).
The preference to drink sweetened water (sucrose preference test) was used as a
measure of anhedonic behaviour. Mice infused with patients’ CSF and tested during the
infusion period (Day 10) had less preference for sucrose compared with mice infused
with control CSF (Fig. 2C). In contrast, the same mice tested 10 days after the infusion
of CSF had stopped (Day 24) showed a preference for sucrose similar to that of the
control mice. The total consumption of water with and without sucrose was similar in
both groups (internal control, Supplementary Table 1). In addition, two tests of
depressive-like behaviour were performed. The tail suspension test, performed on Day
12, showed that animals infused with patients’ CSF had longer periods of immobility
compared with those infused with control CSF (Fig. 2D). In contrast, 6 days after the
infusion of CSF had stopped (Day 20), no differences were noted with the forced
swimming test (examining immobility in inescapable situations; Fig. 2E and
Supplementary Table 1). Overall, these findings suggest that the infusion of NMDAR
antibodies was associated with anhedonic and depressive-like behaviours.
In contrast to the prominent memory deficit, along with anhedonia and depressive
behaviour, no significant differences were noted in tests of anxiety (black and white test,
elevated plus maze test), aggression (resident-intruder test) and locomotor activity (Fig.
3A–D).
Patients’ antibodies bind to NMDAR in mouse brain
Animals infused with patients’ CSF, but not control CSF, had progressively
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increasing human IgG immunostaining (representing IgG bound to brain) that correlated
with the duration of the infusion. The distribution of IgG immunostaining predominated in
regions with high density of NMDAR, mainly the hippocampus (Fig. 4A), resembling that
obtained with brain sections directly incubated with patients’ CSF or a monoclonal
antibody against GluN1 (Dalmau et al., 2008). Upon quantification of immunostaining,
the maximal antibody binding was identified in mice sacrificed on Day 18, which had
received 14 days of CSF infusion, compared with mice sacrificed on Days 5 or 13 (Fig.
4B and C). In animals sacrificed on Days 26 and 46 the presence of IgG immunostaining
progressively decreased. In frontal cortex the dynamics of IgG binding were similar to
those of the hippocampus (Supplementary Fig. 1), but the amount of IgG was
substantially less; in other brain regions such as the cerebellum and striatum, the IgG
immunostaining was sparse and not significantly different between animals infused with
patients’ CSF or control CSF (data not shown).
Studies with immunofluorescence and confocal microscopy showed that in animals
infused with patients’ CSF the presence of hippocampal IgG was visible as a punctate
immunolabelling on the surface of neurons and neuronal processes in contrast to mice
infused with control CSF where minor amounts of IgG reactivity without preference for
neuronal structures were noted (Fig. 4D–G). In addition, the amount of human IgG
bound to all selected regions of hippocampus was significantly higher than in the control
group (Fig. 4H).

To determine if the IgG immunostaining represented brain-bound NMDAR
antibodies, IgG was extracted from several brain regions and examined for reactivity
with HEK cells expressing GluN1. These studies showed that the IgG extracted from
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hippocampus of mice infused with patients’ CSF reacted specifically with GluN1 (Fig.
5A). The NMDAR antibody concentration in the extracts correlated with the duration of
infusion of CSF; it increased until Day 13, reached the maximal concentration on Days
13–18, and decreased afterwards (Fig. 5A and C). NMDAR antibodies were also
detected in IgG extracts from other brain regions (frontal cortex, cerebellum) but at lower
concentration to that obtained from hippocampus (Fig. 5D). Demonstration that the
extracted antibodies were specifically bound to the NMDAR was provided by the lack of
GluN1 reactivity in the pre-extraction fractions (Fig. 5B and E). Parallel studies with
tissue from animals infused with control CSF did not show NMDAR antibodies
(Supplementary Fig. 2).
Effects of patients’ antibodies on NMDAR
To determine the effects of patients’ antibodies on NMDAR, we focused on the
hippocampus, which was the region with maximal concentration of NMDAR-bound
antibodies. Compared with animals infused with control CSF, those infused with patients'
CSF had on Days 13 and 18 a significant decrease of the density of total and synaptic
hippocampal NMDAR clusters followed by a gradual recovery after Day 18 (pooled
analysis of CA1, CA3 and dentate gyrus; Fig. 6A–D). No significant differences in
between hippocampal subregions (CA1, CA3, dentate gyrus) were observed (not
shown). In contrast, patients’ antibodies did not alter the density of PSD95 or AMPAR
clusters (Fig. 6E and F).
Immunoblot analysis of total protein extracted from hippocampus showed that on
Days 13 and 18, mice infused with patients’ CSF had a significant decrease of total
NMDAR protein concentration compared with mice infused with control CSF (Fig. 7A
and B). The magnitude of this effect was greater in animals with higher concentration of
IgG bound to hippocampus (Fig. 7C).

Parallel studies examining the effect
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on the protein concentrations of PSD95 (Fig. 7A and E) and AMPAR (Fig. 7D)
demonstrated no significant differences between mice infused with patients’ CSF or
control CSF.
In cerebellum, no significant effects on the cluster density or total protein
concentration of NMDAR, PSD95 and AMPAR were noted in animals infused with
patients’ CSF compared to those infused with control CSF (data not shown).
Immunohistochemical studies for neuronal apoptosis, infiltrates of T or B cells, and
deposits of complement in hippocampus of animals infused with patients’ or control CSF,
examined on Day 18, showed no abnormalities (Fig. 8).

Discussion
We report that passive transfer of NMDAR antibodies by continuous ventricular
infusion of CSF from patients with anti-NMDAR encephalitis causes memory and
behavioural deficits in mice, and that the effects are likely mediated by the binding of
antibodies to NMDAR resulting in a specific decrease of the density of these receptors.
Data from earlier reports showing that despite the severity and duration of symptoms,
most patients with anti-NMDAR encephalitis respond to immunotherapy (Gresa-Arribas
et al., 2014), and findings at the cellular level demonstrating that patients’ antibodies
cause a titre-dependent decrease of synaptic NMDAR receptors fulfilled most of the
Witebsky’s criteria for an antibody-mediated disease (Rose and Bona, 1993), but the
transfer of symptoms to animals was pending. In the current study, four sets of
experiments satisfy this postulate: (i) the development of symptoms in animals infused
with patients’ CSF, but not control CSF; (ii) the demonstration that the infused antibodies
reacted predominantly with brain regions with high density of NMDAR (e.g.
hippocampus) and specifically

recognized these receptors; (iii) the
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identification of a selective decrease of the density of total and synaptic NMDAR clusters
and total NMDAR protein concentration without affecting PSD95, and that these effects
correlated with the concentration of brain-bound antibodies; and (iv) the correlation
noted between the intensity of the abovementioned findings and time-course of patients’
antibody infusion, as well as between the reversibility of symptoms and restoration of
NMDAR levels after stopping the infusion of CSF antibodies.
Approximately 75% of patients with anti-NMDAR encephalitis present with mood
and psychiatric alterations ranging from manic or depressive behaviour to psychosis,
often followed by stereotyped movements, seizures, or decreased level of
consciousness (Kayser et al., 2013; Titulaer et al., 2013). Regardless of the
presentation, most patients develop severe problems forming new memories and have
amnesia of the disease. Close examination during the phase of recovery shows, in some
patients, impairment in the visual recognition of objects or faces (e.g. physicians, nurses)
(Frechette et al., 2011). Owing to the wide range of symptoms of the disease and lack of
previous studies examining the distribution of brain tissue NMDAR-antibody binding
when these antibodies are infused intraventricularly, we used standardized memory and
behavioural tests. The most notable effects were observed in the tests of memory (novel
object recognition) using different groups of animals in two different paradigms (open
field and V-maze). While the first depends predominantly on normal hippocampal
function, the second is dependent of perirhinal-hippocampal structures (Winters et al.,
2004). Compared with animals infused with control CSF, those infused with patients’
CSF developed progressive memory deficits, which were maximal on Days 13–18 when
the highest concentration of brain-bound NMDAR antibodies and lowest density of
NMDAR occurred. Other paradigms affected were related to depressive-like behaviours
(tail suspension test) and anhedonic

behaviours (sucrose preference test).
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We did not find significant abnormalities in the tests of aggression and anxiety, which are
often present in the human disease, or in locomotor activity (an expected finding given
that paralysis rarely occurs in patients).
The high levels of brain-bound NMDAR antibodies between Days 13–18 suggests
that after stopping the infusion of patients’ CSF on Day 14, the NMDAR antibodies
continued being distributed from mice cerebroventricular system to parenchyma. This
distribution occurred slowly; for example, 5 days after starting the infusion of patients’
CSF the amount of NMDAR antibodies that had reached the hippocampus was very
limited compared to that seen on Days 13–18 (shown in Fig. 4B). Moreover, previous
studies using cultured neurons treated with patients’ CSF showed that once the
antibodies bound to the NMDARs, the reduction of receptors was microscopically visible
in 2 h but it took 12 h to result in the lowest receptor density. Subsequently, there was a
steady state of low NMDAR density for as long as the neurons were exposed to patients’
antibodies (Moscato et al., 2014). Together, these findings explain the progressive
worsening of symptoms along with continued antibody binding and decrease of NMDAR
for at least 4 days after the ventricular infusion stops and the subsequent recovery
starts.
Although the hippocampus was the region with the highest concentration of brainbound NMDAR antibodies, these antibodies were also extracted from cerebral cortex or
cerebellum though at much lower levels. The higher concentration of antibodies and
predominant decrease of NMDAR in the hippocampus are consistent with the
predominant binding of human antibodies to this brain region when sections of rodent
brain are directly incubated with patients’ antibodies (Dalmau et al., 2007; Moscato et al.,
2014). Additionally, because of the close spatial relationship to the ventricles, the
intraventricular infusion of human

CSF antibodies might have contributed
117

to the preferential binding to the hippocampus.
The correlation between the concentration of brain-bound antibodies and selective
reduction of NMDAR cluster density and protein concentration was similar to that
reported using in vitro studies with cultured rat hippocampal neurons (Hughes et al.,
2010; Moscato et al., 2014). Moreover, autopsies of patients with anti-NMDAR
encephalitis showed that the hippocampal regions with highest concentration of brainbound antibodies were also the areas with lower expression of NMDAR (Dalmau et al.,
2007). In the current model, patients’ antibodies did not alter AMPAR cluster density or
protein concentration; these findings are in line with those reported with cultured neurons
where the clusters of AMPAR and AMPAR-mediated currents were not directly affected
(Hughes et al., 2010). These experiments, however, did not explore whether paradigms
that normally induce long-term potentiation, and therefore increase the number of
synaptic AMPAR, were altered by patients’ antibodies. Mikasova et al. (2012) showed
that neurons exposed to patients’ NMDAR antibodies failed to show an increase in cell
surface AMPAR after induction of chemical long-term potentiation. Another study
examining the acute metabolic effects of patients’ antibodies after injection into rat brain
showed impairment of NMDA and AMPA-mediated synaptic function (Manto et al.,
2010). In the present model, we did not perform electrophysiological studies on acute
slices of brain (a goal of future studies); however, there is reported evidence that
patients’ NMDAR antibodies suppress induction of long-term potentiation when directly
applied to mouse hippocampal slices (Zhang et al., 2012). Work with cultured neurons
indicates that the decrease of synaptic NMDAR currents is likely a result of the antibodymediated low receptor levels, as no direct antibody blockade was detected (Moscato et
al., 2014).
Our study has limitations related

to the type of disease and symptoms
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to model. For example, different from other models of antibody-mediated CNS disorders
where the antibodies result in characteristic symptoms (e.g. amphiphysin antibodies and
visible muscle spasms) (Sommer et al., 2005) or focal deficits with visible tissue changes
(e.g. AQP4 antibodies and neuromyelitis optica) (Hinson et al., 2012; Bradl and
Lassmann, 2014), anti-NMDAR encephalitis results in a broader spectrum of symptoms
where memory and behavioural deficits occur early, and the structural alterations are not
visible unless the NMDAR clusters or protein concentration are measured. It is not
surprising that in the current model the full spectrum of symptoms, such as seizures,
dyskinesias or coma, did not occur. Studies with NMDAR antagonists have shown that
the progression of symptoms (from behavioural and memory deficits to
unresponsiveness with catatonic features and coma) correlated with the intensity of the
decrease of receptor function (Javitt and Zukin, 1991). Therefore, it is likely that
prolonged infusion or higher concentration of patients’ antibodies would cause additional
symptoms. This is supported by the current model, in which the time course of symptom
development, brain-bound antibody concentration, and decrease of synaptic NMDAR
correlated well with each other. Future experiments using prolonged infusion or higher
concentration of patients’ antibodies may also result in symptoms beyond hippocampalparahippocampal regions. Compared with the hippocampus, other brain regions
normally have lower density of NMDAR, and appeared to be less accessible to the
ventricularly infused antibodies. Direct injection of antibodies into those brain regions
can be considered, but we previously tried bilateral hippocampal infusion using the same
osmotic pump approach, resulting in more limited antibody diffusion and no symptoms
(data not published). Moreover, the phenotype of the current model is likely influenced
by the strain of mice. In this study we used C57BL6/J mice because we were interested
in the effects on memory and

behaviour, but this strain is one of the
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most resistant to develop seizures (Ferraro et al., 2002).
The antibody-induced depletion of synaptic NMDAR along with the similarities
between the human disease and the phenotypes induced by NMDAR antagonists
(phencyclidine, ketamine or MK801) have suggested points of convergence with one of
the most influential theories of schizophrenia, the NMDA-hypofunction model (Olney and
Farber, 1995; Kehrer et al., 2008). The presence of positive (hallucinations, delusions,
hyperactivity) and negative (decreased motivation, flat affect, deficit of memory and
learning) symptoms is, however, not identical among the drug-induced phenotypes and
also varies among animal species (Javitt and Zukin, 1991). It has been suggested that
NMDAR-bearing parvalbumin-positive GABAergic interneurons are disproportionally
more sensitive to NMDAR antagonists than other neurons (Li et al., 2002). Interestingly,
a genetic model of partial ablation of the GluN1 subunit of NMDAR in corticolimbic
GABAergic interneurons resulted in symptoms partially resembling our GluN1
immunological model of receptor depletion, including memory deficits and anhedonic
behaviours (Belforte et al., 2010). Differences related to the underlying mechanisms
(pharmacologic blockade, genetic or immunologic NMDAR depletion) and regions where
the NMDAR function is depleted (general, corticolimbic, or hippocampalparahippocampal) likely influence the clinical phenotypes.
Overall, the current findings provide robust evidence that antibodies from patients
with anti-NMDAR encephalitis alter memory and behaviour through reduction of cellsurface and synaptic NMDAR, and therefore support the use of treatments directed at
decreasing the levels of antibodies or antibody-producing cells. This approach can now
be adapted to (i) model other aspects of the disease by changing the duration and
dosing of antibody infusion, or strain of mice; (ii) investigate other disorders of memory
and behaviour that occur in

association with antibodies against
120

other cell surface or synaptic proteins, such as AMPAR or GABA(B)R (Lai et al., 2009;
Lancaster et al., 2010); and (iii) determine whether compounds such as Ephrin-B2 ligand
that has been shown to prevent the destabilizing NMDAR crosslinking effects of patients’
antibodies improve or alter the course of the disease (Mikasova et al., 2012).
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Figures
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Figure 1. Experimental design and placement of ventricular catheters.
(A) Representative coronal mouse brain section with catheter placement. Scale bar
= 2 mm. (B and C) Coronal and sagittal mouse brain sections demonstrating
cerebroventricular diffusion of methylene blue after ventricular infusion. Scale bars = 2
mm. (D) Schedule of cognitive testing and animal sacrifice. At Day 0, catheters and
osmotic pumps were placed and bilateral ventricular infusion of patients’ or control CSF
started. Infusion lasted for 14 days. Memory [novel object recognition (NOR)], anhedonia
[sucrose preference test (ANH)], depressive-like behaviour [tail suspension test (TST)
and forced swimming test (FST)], anxiety [black and white test (BW) and elevated plus
maze test (EPM)], aggressiveness [resident intruder test (RI)] and locomotor activity
(LOC) were assessed blinded to treatment at the indicated days. The novel object
recognition was assessed in open field and V-maze paradigms in two different cohorts of
mice. Animals were habituated for 1 to 4 days before surgery (baseline) to novel object
recognition, anhedonia, and locomotor activity. Red arrowheads indicate the days of
sacrifice for studies of effects of antibodies in brain.
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Figure 2. Infusion of CSF from patients with NMDAR antibodies causes deficits in
memory, anhedonia and depressive-like behaviour.
(A and B) Novel object recognition index in open field (A) or V-maze paradigms (B) in
animals treated with patients’ CSF (grey circles) or control CSF (white circles). A high
index indicates better object recognition memory. (C) Preference for sucrose-containing
water in animals infused with patients' CSF (grey) or control CSF (white). Lower
percentages indicate anhedonia. (D and E) Total time of immobility in tail-suspension
test during the infusion period (D, Day 12) and in forced swimming test after the infusion
period (E, Day 20). Data are presented as mean ± SEM (median ± IQR in D). Number of
animals: patients’ CSF n = 18 (open field novel object recognition n = 8), control CSF n =
20 (open field novel object recognition n = 10). Significance of treatment effect was
assessed by two-way ANOVA (A–C) with an α-error of 0.05 and post hoc testing with
Sidak-Holm adjustment (asterisks), unpaired t-test (E) or Mann-Whitney U test (D). *P <
0.05, ***P < 0.001. See Supplementary Table 1 for detailed statistics.
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Figure 3. Infusion of CSF from patients with NMDAR antibodies does not alter the tests
of anxiety, aggression and locomotor activity.
(A and B) Number of entries into bright/open compartments during a 5 min period in a
standard black and white (A, Day 6) or elevated plus maze test (B, Day 14) in animals
treated with patients’ CSF (filled circles) or control CSF (open circles). (C) Number of
aggressive events over a 4-min period in a resident intruder paradigm in both treatment
groups. (D) Horizontal (solid lines) and vertical (dashed lines) movement count over a 10
min period in both treatment groups. Data are presented as mean ± SEM. Number of
animals: patients’ CSF n = 18, control CSF n = 20. Statistical assessment as indicated in
Fig. 2 and Supplementary Table 1.
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Figure 4. Animals infused with patient’s CSF have a progressive increase of human IgG
bound to hippocampus.
(A and B) Immunostaining of human IgG in sagittal brain sections (A) and
hippocampus (B) of representative animals infused with patients’ CSF (left) and control
CSF (right), sacrificed at the indicated experimental days. In animals infused with
patients’ CSF there is a gradual increase of IgG immunostaining until Day 18, followed
by decrease of immunostaining. Scale bars: A = 2 mm; B = 200 µm. (C) Quantification of
intensity of human IgG immunolabelling in hippocampus of mice infused with patients’
CSF (dark grey columns) and control CSF (light grey columns) sacrificed at the indicated
time points. (D–H) Confocal microscopy analysis of IgG bound to the hippocampus on
Day 18. (D) Sagittal section of the hippocampus with areas examined at higher
magnification in E (arrow in CA1), F (arrow heads in CA3) and G (asterisks in dentate
gyrus). Note the fine punctate IgG immunolabelling surrounding neuronal bodies in mice
infused with patients’ CSF; this immunolabelling is similar to that reported in brain
sections directly incubated with patients’ antibodies, as in Dalmau et al. (2008). Scale
bars: D = 200 µm; E–G = 10 µm. (H) Quantification of the intensity of human IgG
immunofluorescence in the indicated areas in animals infused with patients’ CSF (dark
grey columns) or control CSF (light grey columns). For all quantifications, mean intensity
of IgG immunostaining in the group with the highest value (animals treated with patients’
CSF and sacrificed at Day 18) was defined as 100%. All data are presented as mean ±
SEM. For each time point five animals infused with patients’ CSF and five with control
CSF were examined. Significance of treatment effect was assessed by two-way ANOVA
with an α-error of 0.05 (*) and post hoc testing with Sidak-Holm adjustment ($). ***, $$$P
< 0.001; $P < 0.05. See Supplementary Table 2 for detailed statistics.
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Figure 5. The human IgG extracted from brain of mice infused with patients’ CSF is
specific for NMDARs.
(A and B) HEK293 cells expressing the GluN1 subunit of the NMDAR
immunolabelled with acid-extracted IgG fractions (top row in A) or pre-extraction
fractions (top row in B) from hippocampus of mice infused with patients’ CSF and
sacrificed on the indicated days. The maximal reactivity with GluN1-expressing cells was
noted in acid-extracted IgG fractions from Days 13 and 18 (A); none of the pre-extraction
fractions showed GluN1 reactivity (B) indicating that the reactivity of acid-extracted
fractions corresponds to IgG antibodies that were bound to brain NMDAR receptors. The
second row in A and B shows the reactivity with a monoclonal GluN1 antibody, and the
third row the colocalization of immunolabelling. Scale bars = 10 µm. (C) Quantification of
NMDAR antibody titre in IgG-extracted fractions from hippocampus of animals treated
with patients’ CSF (n = 5 mice per each time point, except four mice for Day 5). Solid line
= median. Significance was tested by Kruskal-Wallis with an α-error of 0.05 (asterisks)
and post hoc testing with Dunn’s test ($). **, $$P < 0.01, ***, $$$P < 0.001. See
Supplementary Table 2 for detailed statistics. (D and E) HEK293 cells expressing the
GluN1 subunit of the NMDAR immunolabelled with acid-extracted IgG fractions (D) and
pre-extraction fractions (E) from hippocampus (Hippo), cerebral cortex (Ctx) and
cerebellum (Cb) of mice infused with patients’ CSF (Day 18). The acid-extracted IgG
fraction from hippocampus showed higher level of NMDAR antibodies than those
extracted from cerebral cortex (Ctx) and cerebellum (Cb). Scale bars = 10 µm. n.s = not
significant.
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Figure 6. Patients’ NMDAR antibodies selectively reduce the density of total and
synaptic NMDAR clusters in hippocampus of mice.
(A) Hippocampus of mice infused for 14 days (Day 18) with patients’ CSF (upper
row) or control CSF (lower row) immunolabelled for PSD95 and NMDAR. Images were
merged (merge) and post-processed to demonstrate co-localizing clusters (colocalization). Squares in ‘co-localization’ indicate the analysed areas in CA1, CA3 and
dentate gyrus. Scale bar = 200 µm. (B) Three-dimensional projection and analysis of the
density of total clusters of PSD95 and NMDAR, and synaptic clusters of NMDAR
(defined as NMDAR clusters colocalizing with PSD95) in a representative CA3 region
(square in A ‘co-localization’). Merged images (merge, PSD95 green, NMDAR red) were
post-processed and used to calculate the density of clusters (density = spots/µm3).
Scale bar = 2 µm. (C–F) Quantification of the density of total (C) and synaptic (D)
NMDAR clusters, PSD95 clusters (E), and total/synaptic AMPAR and PSD95 clusters
(Day 18 only, F) in a pooled analysis of hippocampal subregions (CA1, CA3, dentate
gyrus) in animals treated with patients’ CSF (dark grey) or control CSF (light grey) on the
indicated days. Mean density of clusters in control CSF treated animals was defined as
100%. Data are presented as mean ± SEM. For each time point five animals infused
with patients’ CSF and five with control CSF were examined. Significance of treatment
effect was assessed by two-way ANOVA with an α-error of 0.05 (asterisks) and post hoc
testing with Sidak-Holm adjustment ($) (C–E) or unpaired t-test (F). *, $P < 0.05; **, $$P
< 0.01; ***, $$$P < 0.001. See Supplementary Table 2 for detailed statistics.
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Figure 7. Patients’ NMDAR antibodies selectively reduce the protein concentration of
NMDAR in hippocampus of mice.
(A) Representative immunoblots of proteins extracted from hippocampus of animals
infused with patients’ CSF (P) or control CSF (C) sacrificed at the indicated time points
and probed for expression of GluN1 (NMDAR), PSD95 and β-actin (loading control).
Note that there is less visible GluN1 expression on Days 13 and 18. (B, D and E)
Quantification of total NMDAR (B), AMPAR (D) or PSD95 (E) protein in animals treated
with patients’ CSF (filled columns) or control CSF (open columns) sacrificed at the
indicated time points (AMPAR Day 18 only, D). Results were normalized to β-actin
(loading control). Mean band density of animals treated with control CSF was defined as
100%. Data are presented as mean ± SEM. For each time point six animals infused with
patients’ CSF and six with control CSF were examined (for Days 26 and 46, only five
animals treated with patient’s CSF were available). Significance of treatment effect was
assessed by two-way ANOVA with an α-error of 0.05 (asterisks) and post hoc testing
with Sidak-Holm adjustment ($). $$P < 0.01; ***P < 0.001. See Supplementary Table 2
for detailed statistics. (C) Correlation between concentration of human IgG bound to
hippocampus (x-axis, highest hippocampal IgG intensity was defined as 100%) and
hippocampal NMDAR protein concentration in mice sacrificed on Day 18 (R2 = 0.69, P =
0.003). Filled circles: mice infused with patients’ CSF (n = 5), open circles: mice infused
with control CSF (n = 5).
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Figure 8. Absence of neuronal apoptosis, deposits of complement, and lymphocytic
infiltrates in the hippocampus of mice infused with patients’ CSF.
(A and B) TUNEL and cleaved caspase 3 immunolabelling of a representative area
of CA3 (area with maximal IgG binding and lower NMDAR concentration) of an animal
infused with patients’ CSF, showing lack of apoptotic cells. A section of the same region
in an animal with transient middle cerebral artery occlusion (stroke model) shows
apoptotic cells in the penumbra (left).

(C) Same CA3 region as in (A)
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immunostained for C5b-9 showing lack of deposit of complement. A section of the same
region in the indicated stroke model shows presence of complement in the penumbra
(left). (D and E) Same CA3 region as in (A) immunostained for T (CD3) and B (CD45R)
lymphocytes showing absence of inflammatory infiltrates. A section of spleen was used
as control tissue showing the presence of CD3 (green) and CD45R (red) cells. Scale bar
= 10 µm. Total number of animals examined: patients’ CSF n = 5; control CSF n = 5.
Scale bars = 20 µm.
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Abstract
Objective: To report 3 patients who developed anti–N-methyl-D-aspartate receptor
encephalitis during pregnancy.
Design: Case reports.
Setting: University hospitals.
Patients: Three young women developed at 14, 8, and 17 weeks of gestation acute
change of behavior, prominent psychiatric symptoms, progressive decrease of
consciousness, seizures, dyskinesias, and autonomic dysfunction.
Main Outcome Measures: Clinical, radiological, and immunological findings.
Results: The 3 patients had cerebrospinal fluid pleocytosis, normal magnetic
resonance imaging, and electroencephalogram showing slow activity. All had higher
antibody titers in cerebrospinal fluid than in serum and 2 had ovarian teratomas that
were removed. The pregnancy was terminated in 1 patient with recurrent bilateral
teratomas. All patients had substantial neurological recoveries, and the 2 newborns were
normal. Results of extensive antibody testing in 1 of the babies were negative.
Conclusion: The current study shows that anti-NMDAR encephalitis during
pregnancy can have a good outcome for the mother and newborn.

Introduction
Anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis is a synaptic
autoimmune disorder that is likely mediated by antibodies against the NR1 subunit of the
receptor (Dalmau et al., 2008). Despite the severity of the disorder, most patients have
substantial recoveries. Because the disease frequently affects women of childbearing
age and the antibody subtypes (IgG1,

IgG3) can cross the placenta, there is
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concern about the effects of the disorder during pregnancy (Tüzün et al., 2009). We
report 3 patients who developed the disorder during pregnancy.

Report of cases
Clinical features from the patients are described in this section and summarized in
the Table. Antibodies to NMDAR were detected as reported elsewhere (Dalmau et al.,
2008) and the titers were determined by serial dilution (starting at 1:10). The baby of
patient 1 had antibody studies in the umbilical cord, serum, cerebrospinal fluid (CSF),
and amniotic fluid.
Case 1
A 19-year-old woman presented at 14 weeks of gestation with 2 weeks of
headache and malaise followed by bizarre behavior and paranoid delusions resulting in
hospitalization. Over the course of a week, her mental status worsened until she was
minimally responsive. She had a generalized seizure that was treated with fosphenytoin
and lorazepam, and she was intubated for airway protection. A bedside
electroencephalogram (EEG) revealed generalized slowing but no epileptic activity. On
examination, she was minimally responsive to noxious stimuli, had generalized
hyperreflexia, and moved all limbs spontaneously. Results of magnetic resonance
imaging (MRI) and CSF studies are described in the Table. Treatment with acyclovir was
started for presumptive viral encephalitis.
On the third day in the intensive care unit, she developed repetitive pursing of the
lips and furrowing of her brow without EEG correlates. These movements became more
frequent and the dyskinesias spread to her limbs. By day 8, she developed diaphoresis,
tachycardia, mydriasis, and hypertension. These symptoms were difficult to control
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despite treatment with fentanyl, lorazepam, propofol, bromocriptine, and β-blockers.
On day 5, a tracheostomy was performed. Treatment with intravenous
immunoglobulin did not result in improvement. On day 23, an MRI of the abdomen and
pelvis revealed a 2.5 × 3-cm left ovarian simple cyst. On day 43, NMDAR antibodies
were identified in CSF. A second course of intravenous immunoglobulin treatment along
with 1 g of methylprednisolone was given daily for 5 days. On day 50, a left
oophorectomy was performed, revealing an immature teratoma. On day 52,
plasmapheresis was initiated, with a total of 7 treatments over 2 weeks. On day 72, she
became more alert, responded to voice, and tracked objects. Throughout the
hospitalization, the fetus was monitored weekly by Doppler ultrasonography, showing
normal heart tones. Obstetric ultrasonography performed at weeks 20 and 26 revealed
normal fetal anatomy and appropriate growth for gestational age.
The patient remained in the intensive care unit because of persistence of
sympathetic storms. By day 107, she was following simple commands and the sedation
was slowly weaned. On day 127, she began mouthing words. A cesarean section and
concomitant surgical staging was performed on day 166 (at 37 weeks of gestation,
following amniocentesis confirming fetal lung maturity). The infant weighted 6 lb 3 oz and
Apgar scores were 3 at 1 minute and 6 at 5 minutes. All pathological specimens (left
adnexa, pelvic lymph nodes, and peritoneal samples) were negative for tumor. Over the
next 3 days, the patient was weaned from the ventilator and she made steady gains in
physical therapy. By day 184, she was able to ambulate with a walker and her speech
was fluent, but she was only oriented to self. Her progress was hampered by impulsivity,
short-term memory loss, and physical deconditioning. Two months after discharge, she
was functioning independently at home, although she was persistently impulsive and
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complained of somnolence. The infant has met all developmental milestones to date.
Case 2
A 20-year-old woman developed change of behavior during the eighth week of
pregnancy. She became argumentative, refused to talk and eat, and developed
stereotyped behaviors, such as walking endlessly around a room or filling and emptying
a glass with water. Two days before hospital admission, semirhythmic movements
including blinking, licking, and tongue protrusion were noted. One day before admission,
she developed hyperthermia, decreased level of consciousness, and a seizure. She had
a history of bilateral ovarian teratomas that were removed when she was 16 years of
age.
At admission, she had neck stiffness, without fever, and showed repetitive orofacial
movements. She was poorly responsive to verbal and painful stimuli and had
generalized hyperreflexia. Ancillary test results are described in the Table. Intravenous
acyclovir and methylprednisolone administration were started. On day 3, cardiac pauses
up to 5 seconds were noted (Figure, A). Over the next few days, she developed
hypersalivation and generalized tonic convulsions. On day 13, status epilepticus and
respiratory depression led to intubation and mechanical ventilation. On day 15, a pelvic
computed tomographic scan revealed bilateral ovarian tumors (Figure, B, arrows); 2
days later, a left salpingo-oophorectomy and removal of both tumors was performed,
and the pregnancy was terminated. Pathological studies confirmed bilateral mature
teratomas.
From days 23 to 27, she received intravenous immunoglobulin and sedation with
midazolam was discontinued. She gradually started tracking objects and following
commands but continued having partial seizures that were treated with carbamazepine
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and gabapentin. On days 32 to 36, intravenous immunoglobulin administration was
repeated, and by day 43, she was able to breathe spontaneously. By day 52, she was
able to drink; the last seizure was observed on day 53. On day 64, she was eating
regularly, and a few days later, she was able to walk. Her Mini-Mental State Examination
score was 27 of 30 on day 85 and she was discharged home with minimal deficits on
day 87.
Case 3
A 19-year-old pregnant woman presented at 17 weeks of gestation with acuteonset behavioral change, including increasing nervousness, irritability, and anxiety. She
stopped walking and communicating but would say the same word repetitively and was
transferred to a psychiatric facility. Her bizarre behavior continued; for example, she was
frequently hitting the walls, taking cold baths, and accusing the physicians of “being
murderers.” She had fluctuating periods of decreased level of consciousness and
agitation. She had a partial tonic seizure involving the left arm without EEG correlate;
this showed generalized high-amplitude slow activity (2 Hz). Because of progressive
deterioration and the presumptive diagnosis of viral encephalitis, she was transferred 1
week later to a neurology unit. On physical examination, her temperature was 37.1°C,
and she had no neck stiffness. She developed hyperhidrosis and repetitive semirhythmic
oral movements, like automatisms. Brain computed tomography and MRI were normal.
The CSF showed lymphocytic pleocytosis (white blood cell count, 11/μL) with normal
protein and glucose concentrations. Results of extensive viral studies and autoimmune
and paraneoplastic markers were negative. Anti-NMDAR antibodies were identified in
her serum and CSF. A second EEG showed no changes compared with the previous
study. Magnetic resonance imaging of the abdomen and pelvis and abdominal
ultrasonography were normal.
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From day 19, the patient was treated with intravenous methylprednisolone (500
mg/d for 5 days) without clinical improvement, and a similar course of
methylprednisolone treatment was started on day 35. After this second treatment, the
orofacial dyskinesias subsided, but she continued with a decreased level of
consciousness. On day 54, she had a generalized tonic-clonic seizure and treatment
with phenobarbital was started. One month later, her level of consciousness started to
progressively improve. Throughout the hospitalization, she did not develop
hypoventilation. The fetus was monitored regularly by Doppler ultrasonography, showing
normal heart tones. At 37 weeks of pregnancy, she spontaneously delivered a healthy
2892-g baby with Apgar scores of 8 at 1 minute and 9 at 5 minutes. Her Mini-Mental
State Examination score was 24 of 30, and she was discharged 3 weeks later. At the
last follow-up, she was fully functional and had returned to work. The child remains
healthy with no obvious adverse effects.

Detection of NMDAR antibodies
All 3 patients had higher NMDAR antibody titers in CSF than serum (Table). No
antibodies were identified in the amniotic fluid, umbilical cord blood, serum, or CSF from
the baby of patient 1. The baby of the other patient was not examined for antibodies.

Comment
To our knowledge, these are the first reported patients with anti-NMDAR
encephalitis diagnosed during pregnancy. The 3 patients had substantial neurological
recoveries, although in 1 case the pregnancy was terminated because of the severity of
neurological symptoms, presence of recurrent bilateral teratomas, and early stage of
pregnancy. The newborns of the other 2 patients were healthy and their physical and
cognitive milestones are being

closely followed up. Concern for the
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fetus and newborns is warranted in this disorder as studies indicate that NR1 antibodies
from patients decrease NMDAR clusters in vitro and in animal models (Dalmau et al.,
2008; Hughes et al., 2010). Moreover, the antibodies are IgG1 and IgG3, which are the
subtypes involved in autoimmune newborn illnesses, such as congenital lupus (Hoftman
et al., 2008).
The good outcome of the 2 neonates of our study is likely due to several factors,
including the variable effects of autoimmune disorders on the fetus. For example,
despite experimental models showing that Ro/SSA antibodies cause congenital heart
block, only 2% to 5% of neonates from patients with these antibodies have congenital
heart block (Brucato et al., 2002). Two additional factors relate to the levels of serum
maternal antibodies and the timing of transplacental transfer of IgG. IgG1 and IgG3
cross the placenta by binding to an Fc neonatal receptor present in syncytiotrophoblasts
(Roopenian and Akilesh, 2007). This mechanism of placental transfer develops around
weeks 14 to 16, resulting initially in very low levels of fetal blood IgG that gradually
increase until the time of delivery. Additionally, the fetal blood-brain barrier becomes
functional by the end of the second trimester. Our patients developed symptoms
between 8 and 17 weeks of pregnancy when the IgG placental transfer is absent or
limited, and assuming the immune response was triggered systemically, the levels of
serum NMDAR antibodies decreased rapidly. In fact, 2 patients had negative serum but
positive CSF antibody titers (both tested at initial dilution 1:10) by the time they were
diagnosed with anti-NMDAR encephalitis, explaining the absence of NMDAR antibodies
in the baby who was tested.
With a sharp increase in the number of cases with anti-NMDAR encephalitis, more
patients will be identified during pregnancy. This study suggests that these patients and
the newborns can do well. The

concern should be the search (and
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removal) of a teratoma along with supportive care of the mother and fetus. Treatment
with corticosteroids, intravenous immunoglobulin, and plasmapheresis was well tolerated
but the effects could not be assessed because of the close temporal association with
tumor removal in 2 patients. The third patient only received corticosteroids, with
questionable improvement of the dyskinesias. The recovery seemed to accelerate after
giving birth; this and the predominance of the disorder in young women bring into
consideration a possible role of hormonal factors that needs further study.
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Figures
Figure 1. Cardiac pauses and bilateral teratomas in patient 2.
A, Cardiac pauses up to 5 seconds were noted on day 3 of hospital admission. B, A
pelvic computed tomographic scan revealed bilateral recurrent teratomas (arrows).
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CHAPTER 5. Conclusion
Each of the clinical syndromes under the umbrella of autoimmune encephalitis is an
opportunity to not only understand the mechanism by which the human body fails to
distinguish self from non-self but also how autoantibodies cause neuropsychiatric
disease. The basic science and translational work on the unique aspects on each of the
autoimmune encephalitides underscores that despite a failure in immunotolerance,
cellular and humoral factors can disrupt their target antigen in distinct ways.
Although the molecular and cellular effects of the antibodies are being rapidly
resolved, the effects of the antibody-mediated disruption of synaptic proteins on network
and circuit properties are still largely unknown. Extrapolating from the clinical effects of
the pathogenic antibodies and from the known functions of the antigenic synaptic
components, one can expect that in patients, circuit abnormalities such as altered
excitation-inhibition balance, aberrant homeostatic synaptic scaling, loss of synaptic
plasticity, reentrant feedback loops result in neuropsychiatric manifestations such as
psychotic behavior, impaired memory formation, seizures or movement disorders.
Studies in animal models and patients will provide insights into the circuit alterations
caused by antibodies that result in aberrant behavior.
A major gap in understanding of CNS autoimmune diseases exists in identification
of mechanisms at the interface between the nervous and the immune systems. The
current literature strongly supports the model that autoreactive T and B cells extravasate
into the parenchymal and perivascular spaces in the CNS where they may survey the
inflammatory state of the neuronal tissues that in turn affects the maturation of these
lymphocytes. Our understanding of
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mediated factors and their effects on neurons and glia is burgeoning, but is currently in
its infancy.
The mechanism by which GABAB autoantibodies result in disease is just beginning
to be understood. Until this work, all autoimmune encephalitides described were
associated with autoantibodies that reduced the levels of cognate receptors. I have
shown that GABAB receptor autoantibodies directly block GABAB receptor activation by
baclofen, suggesting that the clinical manifestations of GABAB receptor autoantibodies
result from diminished GABAB receptor function. Patient GABAB receptor autoantibodies
do not inactivate GABAB receptors, however, because the patient antibody mediated
baclofen block was circumvented by directly activating the GABAB2 subunit with a
selective partial allosteric agonist, CGP7930. This provides hope that newly developed
brain penetrant GABAB2 agonists may be used to treat the intractable seizures that are
the primary cause of morbidity and mortality in anti-GABAB receptor encephalitis
patients.
The Sushi domains present in the presynaptically localized GABAB(1a,2) receptors is
the immunodominant domain recognized by GABAB receptor. How the binding to this
domain blocks the activation of GABAB1 receptors by agonists is unclear. Currently, it is
thought that the function of sushi domains is to target GABAB1a to the axonal domain of
neurons. While patient autoantibodies are GABAB receptor antagonists, it is possible that
autoantibodies also affect receptor trafficking and presynaptic localization by blocking
the two Sushi domains. This can be tested by probing whether patient antibodies can
result in a loss of polarity of the distribution a sushi domain containing peptide in cell
culture. Our work raises the possibility that sushi domains may have functions other than
polar trafficking that are important for the activation of GABAB1a receptors. Specifically, it
would be valuable to demonstrate

that GABAB autoantibodies block
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GABAB1a containing receptors but not GABAB1b containing receptors. If this is true, the
patient GABAB autoantibodies would be a valuable research tool to dissect the distinct
contributions of GABAB1a and GABAB1b in GABA mediated neurotransmission, and be a
model for therapeutic strategies that target GABAB1a mediated signaling but not GABAB1b
mediated signaling.
The development of the in vivo model of anti-NMDA receptor encephalits enables
several lines of investigation, with relevance to both clinical management of this disease
and our understanding of the role of NMDA receptors in circuits, cognition and behavior.
A potential blocking peptide that disrupts the ability of the pathogenic antibody to bind to
NMDA receptors can be studied. Also, the hypothesis that the Ephrin receptor
interaction is necessary for the pathogenic effect of NMDA receptor autoantibodies can
be tested.
Infusion into the cerebral ventricles delivers the pathogenic antibody to nearly every
brain structure, and it is unclear what circuits are compromised by the autoantibody to
cause a decline in spatial object memory. Focused intraparenchymal infusion of patient
CSF with concomitant electrophysiological recording will enable us to pinpoint the
defects in circuit function and plasticity that underlies the currently observed spatial
memory deficit.
Understanding the mechanisms of recovery after widespread loss of NMDA
receptors is of utmost clinical importance. Interestingly, clearance of anti-neuronal
antibodies is not a good predictor of amelioration of symptoms. Long after antibodies are
undetectable in serum or CSF, patients remain functionally compromised. It can take up
to two years for a full return to work and normal routine and sometimes even years after
treatment people are left with cognitive deficiencies. In culture, receptor levels return to
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baseline 3-4 days after antibody removal and in the animal model, immunoglobulin
clearance and recovery of NMDARs is complete within twelve days of cessation of
antibody infusion. In patients’ brains, which may have been exposed to autoantibodies
for months, the loss of NMDA-mediated glutamatergic transmission may have resulted in
a cascade of changes, both within and between neurotransmitter systems. As antibody
titers fall, even though receptor density returns to normal, the brain may require
additional time to reset to its pre-disease baseline. The animal model can be used to
probe changes in other neurotransmitter systems and kinetics of these changes that
may hopefully shed light on the downstream effects of a global reduction in NMDA
receptor functioning.
These diseases offer human models of brain-immune interactions in which the
target antigens have critical roles in neuronal synaptic transmission and plasticity.
Patient antibodies have proven to be potent tools with no commercial equivalent that
enable the roles of target proteins to be addressed at the synaptic, cellular, circuit and
behavioral levels. Studies of mechanisms underlying recovery of function as well as
lingering effects on behavior as antibody titers are reduced will also be important.
Ongoing work may lead to targeted therapeutic strategies for autoimmune encephalitis,
and will also provide an unprecedented window into the in vivo role of key synaptic
components essential for neuronal communication, circuit function and behavior.
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